Albumin variants

ABSTRACT

The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

REFERENCE TO A SEQUENCE LISTING

This application contains a Sequence Listing in computer readable form,which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates to variants of albumin or fragments thereof orfusion polypeptides comprising variant albumin or fragments thereofhaving a change in binding affinity to FcRn and/or a change in half-lifecompared to the albumin, fragment thereof or fusion polypeptidecomprising albumin or a fragment thereof. The invention allows tailoringof binding affinity and/or half-life of an albumin to the requirementsand desires of a user or application.

2. Description of the Related Art

Albumin is a protein naturally found in the blood plasma of mammalswhere it is the most abundant protein. It has important roles inmaintaining the desired osmotic pressure of the blood and also intransport of various substances in the blood stream. Albumins have beencharacterized from many species including human, pig, mouse, rat, rabbitand goat and they share a high degree of sequence and structuralhomology.

Albumin binds in vivo to its receptor, the neonatal Fc receptor (FcRn)“Brambell” and this interaction is known to be important for the plasmahalf-life of albumin. FcRn is a membrane bound protein, expressed inmany cell and tissue types. FcRn has been found to salvage albumin fromintracellular degradation (Roopenian D. C. and Akilesh, S. (2007), Nat.Rev. Immunol 7, 715-725.). FcRn is a bifunctional molecule thatcontributes to maintaining a high level of IgGs and albumin in serum inmammals such as human beings.

Whilst the FcRn-immunoglobulin (IgG) interaction has been characterizedin the prior art, the FcRn-albumin interaction is less wellcharacterized. The major FcRn binding site is localized within DIII(381-585), (Andersen et al (2010), Clinical Biochemistry 43, 367-372). Anumber of key amino acids have been shown to be important in binding,notably histidines H464, H510 and H536 and Lys500 (Andersen et al(2010), Nat. Commun. 3:610. DOI:10.1038/ncomms1607). Data indicates thatIgG and albumin bind non-cooperatively to distinct sites on FcRn(Andersen et al. (2006), Eur. J. Immunol 36, 3044-3051; Chaudhury et al.(2006), Biochemistry 45, 4983-4990.).

It is known that mouse FcRn binds IgG from mice and humans whereas humanFcRn appears to be more discriminating (Ober et al. (2001) Int. Immunol13, 1551-1559). Andersen et al. (2010) Journal of Biological Chemistry285(7):4826-36, describes the affinity of human and mouse FcRn for eachmouse and human albumin (all possible combinations). No binding ofalbumin from either species was observed at physiological pH to eitherreceptor. At acidic pH, a 100-fold difference in binding affinity wasobserved. In all cases, binding of albumin and IgG from either speciesto both receptors were additive.

Human serum albumin (HSA) has been well characterized as a polypeptideof 585 amino acids, the sequence of which can be found in Peters, T.,Jr. (1996) All about Albumin: Biochemistry, Genetics and Medical,Applications pp 10, Academic Press, Inc., Orlando (ISBN 0-12-552110-3).It has a characteristic binding to its receptor FcRn, where it binds atpH 6.0 but not at pH 7.4.

The plasma half-life of HSA has been found to be approximately 19 days.A natural variant having lower plasma half-life has been identified(Peach, R. J. and Brennan, S. 0., (1991) Biochim Biophys Acta.1097:49-54) having the substitution D494N. This substitution generatedan N-glycosylation site in this variant, which is not present in thewild-type albumin. It is not known whether the glycosylation or theamino acid change is responsible for the change in plasma half-life.

Albumin has a long plasma half-life and because of this property it hasbeen suggested for use in drug delivery. Albumin has been conjugated topharmaceutically beneficial compounds (WO2000/69902), and it was foundthat the conjugate maintained the long plasma half-life of albumin. Theresulting plasma half-life of the conjugate was generally considerablylonger than the plasma half-life of the beneficial therapeutic compoundalone.

Further, albumin has been genetically fused to therapeuticallybeneficial peptides (WO 2001/79271 A and WO2003/59934) with the typicalresult that the fusion has the activity of the therapeuticallybeneficial peptide and a considerably longer plasma half-life than theplasma half-life of the therapeutically beneficial peptides alone.

Otagiri et al (2009), Biol. Pharm. Bull. 32(4), 527-534, discloses morethan 70 albumin variants, of these 25 of these are found to be mutatedin domain III. A natural variant lacking the last 175 amino acids at thecarboxy termini has been shown to have reduced half-life (Andersen et al(2010), Clinical Biochemistry 43, 367-372). Iwao et al (2007) studiedthe half-life of naturally occurring human albumin variants using amouse model, and found that K541E and K560E had reduced half-life, E501Kand E570K had increased half-life and K573E had almost no effect onhalf-life (Iwao, et. al. (2007) B.B.A. Proteins and Proteomics 1774,1582-1590). Galliano et al (1993) Biochim. Biophys. Acta 1225, 27-32discloses a natural variant E505K. Minchiotti et al (1990) discloses anatural variant K536E. Minchiotti et al (1987) Biochim. Biophys. Acta916, 411-418, discloses a natural variant K574N. Takahashi et al (1987)Proc. Natl. Acad. Sci. USA 84, 4413-4417, discloses a natural variantD550G. Carlson et al (1992). Proc. Nat. Acad. Sci. USA 89, 8225-8229,discloses a natural variant D550A.

WO2011/051489 and WO 2012/150319 (PCT/EP2012/058206) disclose a numberof point mutations in albumin which modulate the binding of albumin toFcRn, WO2010/092135 discloses a number of point mutations in albuminwhich increase the number of thiols available for conjugation in thealbumin, the disclosure is silent about the effect of the mutations onthe binding of the albumin to FcRn. WO2011/103076 discloses albuminvariants, each containing a substitution in Domain III of HSA.WO2012/112188 discloses albumin variants containing substitutions inDomain III of HSA.

Albumin has the ability to bind a number of ligands and these becomeassociated (associates) with albumin. This property has been utilized toextend the plasma half-life of drugs having the ability tonon-covalently bind to albumin. This can also be achieved by binding apharmaceutical beneficial compound, which has little or no albuminbinding properties, to a moiety having albumin binding properties, seereview article and reference therein, Kratz (2008) Journal of ControlledRelease 132, 171-183.

Albumin is used in preparations of pharmaceutically beneficialcompounds, in which such a preparation maybe for example, but notlimited to, a nanoparticle or microparticle of albumin. In theseexamples the delivery of a pharmaceutically beneficial compound ormixture of compounds may benefit from alteration in the albumin'saffinity to its receptor where the beneficial compound has been shown toassociate with albumin for the means of delivery. It is not clear whatdetermines the plasma half-life of the formed associates (for examplebut not limited to Levemir®, Kurtzhals P et al. Biochem. J. 1995;312:725-731), conjugates or fusion polypeptides but it appears to be aresult of the combination of the albumin and the selectedpharmaceutically beneficial compound/polypeptide. It would be desirableto be able to control the plasma half-life of given albumin conjugates,associates or albumin fusion polypeptides so that a longer or shorterplasma half-life can be achieved than given by the components of theassociation, conjugation or fusion, in order to be able to design aparticular drug according to the particulars of the indication intendedto be treated.

Albumin is known to accumulate and be catabolized in tumors; it has alsobeen shown to accumulate in inflamed joints of rheumatoid arthritissufferers. See review article and reference therein, Kratz (2008)Journal of Controlled Release 132, 171-183. It is envisaged that HSAvariants with increased affinity for FcRn would be advantageous for thedelivery of pharmaceutically beneficial compounds.

It may even be desirable to have variants of albumin that have little orno binding to FcRn in order to provide shorter half-lives or controlledserum pharmacokinetics as described by Kenanova et al (2009) J. Nucl.Med.; 50 (Supplement 2):1582).

Kenanova et al (2010, Protein Engineering, Design & Selection 23(10):789-798; WO2010/118169) discloses a docking model comprising astructural model of domain III of HSA (solved at pH 7 to 8) and astructural model of FcRn (solved at pH 6.4). Kenanova et al disclosesthat positions 464, 505, 510, 531 and 535 in domain III potentiallyinteract with FcRn. The histidines at positions 464, 510 and 535 wereidentified as being of particular interest by Chaudhury et al., (2006,op. cit.) and these were shown to have a significant reduction inaffinity and shorter half-life in mouse by Kenanova (2010, op. cit.).However, the studies of Kenanova et al are limited to domain III of HSAand therefore do not consider HSA in its native intact configuration.Furthermore, the identified positions result in a decrease in affinityfor the FcRn receptor.

The present invention provides further variants having modulated (i.e.altered) binding affinity to the FcRn receptor. The albumin moiety ormoieties may therefore be used to tailor the binding affinity to FcRnand/or half-life of fusion polypeptides, conjugates, associates,nanoparticles and compositions comprising the albumin moiety.

SUMMARY OF THE INVENTION

The present invention relates to albumin variants comprising one or more(several) alterations in Domain I and one or more (several) alterationsin Domain III of the mature polypeptide of SEQ ID NO: 2 or equivalentpositions of other albumins or fragments thereof.

The present invention also relates to albumin variants comprising one ormore (several) alterations in Domain I of the mature polypeptide of SEQID NO: 2 or equivalent positions of other albumins or fragments thereof.

The present invention also relates to albumin variants comprising one ormore (several) alterations in Domain III of the mature polypeptide ofSEQ ID NO: 2 or equivalent positions of other albumins or fragmentsthereof.

The present invention also relates to isolated polynucleotides encodingthe variants; nucleic acid constructs, vectors, and host cellscomprising the polynucleotides; and methods of producing the variants.

The invention also relates to conjugates or associates comprising thevariant albumin or fragment thereof according to the invention and abeneficial therapeutic moiety or to a fusion polypeptide comprising avariant albumin or fragment thereof of the invention and a fusionpartner polypeptide.

The invention further relates to compositions comprising the variantalbumin, fragment thereof, fusion polypeptide comprising variant albuminor fragment thereof or conjugates comprising the variant albumin orfragment thereof, according to the invention or associates comprisingthe variant albumin or fragment thereof, according to the invention. Thecompositions are preferably pharmaceutical compositions.

The invention further relates to a pharmaceutical composition comprisinga variant albumin, fragment thereof, fusion polypeptide comprisingvariant albumin or fragment thereof or conjugates comprising the variantalbumin or fragment thereof, or associates comprising the variantalbumin or fragment thereof.

The invention also relates to the use of the variants, fragments, fusionpolypeptides, conjugates, associates, nanoparticles and microparticles.

The invention also relates to a method for preparing a variant albumin,fragment thereof, fusion polypeptide comprising variant albumin orfragment thereof or conjugates comprising the variant albumin orfragment thereof, or associates comprising the variant albumin orfragment thereof.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1: Multiple alignment of amino acid sequences of (i) full lengthmature HSA (Hu_(—)1_(—)2_(—)3), (ii) an albumin variant comprisingdomain I and domain III of HSA (Hu_(—)1_(—)3), (iii) an albumin variantcomprising domain II and domain III of HSA (Hu_(—)2_(—)3), (iv)full-length Macaca mulatta albumin (Mac_mul), (v) full-length Rattusnorvegicus albumin (Rat) and (vi) full-length Mus musculus albumin(Mouse). Positions 500, 550 and 573 (relative to full length HSA) areindicated by arrows. In FIG. 1 Domains I, II and III are referred to as1, 2 and 3 (respectively).

FIG. 2: Multiple alignment of amino acid sequence of mature albumin fromhuman, sheep, mouse, rabbit and goat and immature albumins fromchimpanzee (“Chimp”), macaque, hamster, guinea pig, rat, cow, horse,donkey, dog, chicken, and pig. The Start and End amino acids of domains1, 2 and 3 (as defined by Dockal et al (The Journal of BiologicalChemistry, 1999, Vol. 274(41): 29303-29310)) are indicated with respectto mature human albumin.

FIG. 3: Conserved groups of amino acids based on their properties.

FIG. 4: Representation of shFcRn-HSA docking model. (A-B) Twoorientations of the complex are shown. Albumin is shown by aspace-filling diagram, FcRn is shown as a ribbon diagram. The corebinding interface of HSA is highlighted in pink (in grey-scale this isseen as the darkest (almost black) region; DI (CBI)), while the areadistally localized from the interface is shown as DII (orange) and DIIIis split into sub-domains DIIIa (in colour, this is cyan) and DIIIb (incolour, this is blue).

FIG. 5: shFcRn binding of WT HSA, HSA K573P and HSA N111Q/K573P atpH5.5, samples were injected over immobilized shFcRn-HIS (1500-2500 RU)at pH 5.5.

FIG. 6: A proposed shFcRn-HSA docking model, showing the spatialrelationship between shFcRn (space filling diagram) and HSA (ribbondiagram) DI, DII and DIII including loops of HSA comprising positions 78to 88 and 108 to 112.

DEFINITIONS

Variant: The term “variant” means a polypeptide derived from a parentalbumin by one or more (several) alteration(s), i.e., a substitution,insertion, and/or deletion, at one or more (several) positions. Asubstitution means a replacement of an amino acid occupying a positionwith a different amino acid; a deletion means removal of an amino acidoccupying a position; and an insertion means adding 1 or more (several),such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 1 to 3 amino acidsimmediately adjacent an amino acid occupying a position. In relation tosubstitutions, ‘immediately adjacent’ may be to the N-side (‘upstream’)or C-side (‘downstream’) of the amino acid occupying a position (‘thenamed amino acid’). Therefore, for an amino acid named/numbered ‘X’, theinsertion may be at position ‘X+1’ (‘downstream’) or at position ‘X-1’(‘upstream’).

Mutant: The term “mutant” means a polynucleotide encoding a variant.

Wild-Type Albumin: The term “wild-type” (WT) albumin means albuminhaving the same amino acid sequence as naturally found in an animal orin a human being.

Parent Albumin: The term “parent” or “parent albumin” means an albuminto which an alteration is made by the hand of man to produce the albuminvariants of the invention. The parent may be a naturally occurring(wild-type) polypeptide or an allele thereof, or even a variant thereof.

Albumin: Albumins are proteins and constitute the most abundant proteinin plasma in mammals and albumins from a long number of mammals havebeen characterized by biochemical methods and/or by sequenceinformation. Several albumins, e.g., human serum albumin (HSA), havealso been characterized crystallographically and the structuredetermined (HSA: He X M, Carter D C (July 1992). “Atomic structure andchemistry of human serum albumin”. Nature 358 (6383): 209-15; horsealbumin: Ho, J. X. et al. (2001). X-ray and primary structure of horseserum albumin (Equus caballus) at 0.27-nm resolution. Eur J. Biochem.215(1):205-12).

The term “albumin” means a protein having the same and/or very similarthree dimensional (tertiary) structure as HSA or HSA domains and hassimilar properties to HSA or to the relevant domains. Similar threedimensional structures are for example the structures of the albuminsfrom the species mentioned herein. Some of the major properties ofalbumin are i) its ability to regulate plasma volume (oncotic activity),ii) a long plasma half-life of around 19 days±5 days, iii) binding toFcRn, iv) ligand-binding, e.g. binding of endogenous molecules such asacidic, lipophilic compounds including bilirubin, fatty acids, hemin andthyroxine (see also Table 1 of Kragh-Hansen et al, 2002, Biol. Pharm.Bull. 25, 695, hereby incorporated by reference), v) binding of smallorganic compounds with acidic or electronegative features e.g. drugssuch as warfarin, diazepam, ibuprofen and paclitaxel (see also Table 1of Kragh-Hansen et al, 2002, Biol. Pharm. Bull. 25, 695, herebyincorporated by reference). Not all of these properties need to befulfilled to in order to characterize a protein or fragment as analbumin. If a fragment, for example, does not comprise a domainresponsible for binding of certain ligands or organic compounds thevariant of such a fragment will not be expected to have these propertieseither.

Albumins have generally a long plasma half-life of approximately 20 daysor longer, e.g., HSA has a plasma half-life of 19 days. It is known thatthe long plasma half-life of HSA is mediated viainteraction with itsreceptor FcRn, however, an understanding or knowledge of the exactmechanism behind the long half-life of HSA is not essential for theinvention.

As examples of albumin proteins according to the invention can bementioned human serum albumin (e.g. AAA98797 or P02768-1, SEQ ID NO: 2(mature), SEQ ID NO: 4 (immature)), primate serum albumin, (such aschimpanzee serum albumin (e.g. predicted sequence XP_(—)517233.2 SEQ IDNO: 5), gorilla serum albumin or macaque serum albumin (e.g.NP_(—)001182578, SEQ ID NO: 6), rodent serum albumin (such as hamsterserum albumin (e.g. A6YF56, SEQ ID NO: 7), guinea pig serum albumin(e.g. Q6WDN9-1, SEQ ID NO: 8), mouse serum albumin (e.g. AAH49971 orP07724-1 Version 3, SEQ ID NO: 9) and rat serum albumin (e.g. AAH85359or P02770-1 Version 2, SEQ ID NO: 10))), bovine serum albumin (e.g. cowserum albumin P02769-1, SEQ ID NO: 11), equine serum albumin such ashorse serum albumin (e.g. P35747-1, SEQ ID NO: 12) or donkey serumalbumin (e.g. Q5XLE4-1, SEQ ID NO: 13), rabbit serum albumin (e.g.P49065-1 Version 2, SEQ ID NO: 14), goat serum albumin (e.g. ACF10391,SEQ ID NO: 15), sheep serum albumin (e.g. P14639-1, SEQ ID NO: 16), dogserum albumin (e.g. P49822-1, SEQ ID NO: 17), chicken serum albumin(e.g. P19121-1 Version 2, SEQ ID NO: 18) and pig serum albumin (e.g.P08835-1 Version 2, SEQ ID NO: 19) or a polypeptide having at least 70,75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or at least 99% aminoacid identity to such an albumin. The parent or reference albumin may bean artificial variant such as HSA K573P (SEQ ID NO: 3) or a chimericalbumin such as the N-terminal of HSA and the C-terminal of macacaalbumin (SEQ ID NO: 20), N-terminal of HSA and the C-terminal of mousealbumin (SEQ ID NO: 21), N-terminal of HSA and the C-terminal of rabbitalbumin (SEQ ID NO: 22), N-terminal of HSA and the C-terminal of sheepalbumin (SEQ ID NO: 23).

Other examples of albumin, which are also included in the scope of thisapplication, include ovalbumin (e.g. P01012.pro: chicken ovalbumin;O73860.pro: turkey ovalbumin).

HSA as disclosed in SEQ ID NO: 2 or any naturally occurring allelethereof, is the preferred albumin (parent albumin) according to theinvention. HSA is a protein consisting of 585 amino acid residues andhas a molecular weight of 67 kDa. In its natural form it is notglycosylated. The skilled person will appreciate that natural allelesmay exist having essentially the same properties as HSA but having oneor more (several) amino acid changes compared to SEQ ID NO: 2, and theinventors also contemplate the use of such natural alleles as parentalbumin according to the invention.

The parent albumin, a fragment thereof, or albumin part of a fusionpolypeptide comprising albumin or a fragment thereof according to theinvention preferably has a sequence identity to the sequence of HSAshown in SEQ ID NO: 2 of at least 60%, preferably at least 70%,preferably at least 80%, preferably at least 85%, preferably at least86%, preferably at least 87%, preferably at least 88%, preferably atleast 89%, preferably at least 90%, preferably at least 91%, preferablyat least 92%, preferably at least 93%, preferably at least 94%,preferably at least 95%, more preferred at least 96%, more preferred atleast 97%, more preferred at least 98% and most preferred at least 99%.It is preferred that the parent albumin maintains at least one of themajor properties of albumin or a similar tertiary structure as analbumin, such as HSA The sequence identity may be over the full-lengthof SEQ ID NO: 2 or over a molecule consisting or comprising of afragment such as one or more (several) domains of SEQ ID NO: 2 such as amolecule consisting of or comprising domain III (e.g. SEQ ID NO: 27), amolecule consisting of or comprising domain II and domain III (e.g. SEQID NO: 25), a molecule consisting of or comprising domain I and domainIII (e.g. SEQ ID NO: 24), a molecule consisting of or comprising twocopies of domain III (e.g. SEQ ID NO: 26), a molecule consisting of orcomprising three copies of domain III (e.g. SEQ ID NO: 28) or a moleculeconsisting of or comprising domain I and two copies of domain III (e.g.SEQ ID NO: 29).

The parent preferably comprises or consists of the amino acid sequenceof SEQ ID NO: 4 (immature sequence of HSA) or SEQ ID NO: 2 (maturesequence of HSA).

In another embodiment, the parent is an allelic variant of the maturepolypeptide of SEQ ID NO: 2.

The parent albumin may be encoded by a polynucleotide that hybridizesunder very low stringency conditions, low stringency conditions, mediumstringency conditions, medium-high stringency conditions, highstringency conditions, or very high stringency conditions with (i) themature polypeptide coding sequence of SEQ ID NO: 1, or (ii) thefull-length complementary strand of (i) (J. Sambrook, E. F. Fritsch, andT. Maniatis, 1989, Molecular Cloning, A Laboratory Manual, 2d edition,Cold Spring Harbor, N.Y.).

The polynucleotide of SEQ ID NO: 1 or a subsequence thereof, as well asthe amino acid sequence of SEQ ID NO: 2 or a fragment thereof, may beused to design nucleic acid probes to identify and clone DNA encoding aparent from strains of different genera or species according to methodswell known in the art. In particular, such probes can be used forhybridization with the genomic or cDNA of the genus or species ofinterest, following standard Southern blotting procedures, in order toidentify and isolate the corresponding gene therein. Such probes can beconsiderably shorter than the entire sequence, but should be at least14, e.g., at least 25, at least 35, or at least 70 nucleotides inlength. Preferably, the nucleic acid probe is at least 100 nucleotidesin length, e.g., at least 200 nucleotides, at least 300 nucleotides, atleast 400 nucleotides, at least 500 nucleotides, at least 600nucleotides, at least 700 nucleotides, at least 800 nucleotides, or atleast 900 nucleotides in length. Both DNA and RNA probes can be used.The probes are typically labelled for detecting the corresponding gene(for example, with ³²P, ³H, ³⁵5, biotin, or avidin). Such probes areencompassed by the invention.

A genomic DNA or cDNA library prepared from such other organisms may bescreened for DNA that hybridizes with the probes described above andencodes a parent. Genomic or other DNA from such other organisms may beseparated by agarose or polyacrylamide gel electrophoresis, or otherseparation techniques. DNA from the libraries or the separated DNA maybe transferred to and immobilized on nitrocellulose or other suitablecarrier material. In order to identify a clone or DNA that is homologouswith SEQ ID NO: 1 or a subsequence thereof, the carrier material is usedin a Southern blot.

For purposes of the invention, hybridization indicates that thepolynucleotide hybridizes to a labelled nucleotide probe correspondingto the polynucleotide shown in SEQ ID NO: 1, its complementary strand,or a subsequence thereof, under low to very high stringency conditions.Molecules to which the probe hybridizes can be detected using, forexample, X-ray film or any other detection means known in the art.

The nucleic acid probe may comprise or consist of the mature polypeptidecoding sequence of SEQ ID NO: 1, i.e. nucleotides 1 to 1785 of SEQ IDNO: 1. The nucleic acid probe may comprise or consist of apolynucleotide that encodes the polypeptide of SEQ ID NO: 2 or afragment thereof.

For long probes of at least 100 nucleotides in length, very low to veryhigh stringency conditions are defined as pre-hybridization andhybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml shearedand denatured salmon sperm DNA, and either 25% formamide for very lowand low stringencies, 35% formamide for medium and medium-highstringencies, or 50% formamide for high and very high stringencies,following standard Southern blotting procedures for 12 to 24 hoursoptimally. The carrier material is finally washed three times each for15 minutes using 2×SSC, 0.2% SDS at 45° C. (very low stringency), 50° C.(low stringency), 55° C. (medium stringency), 60° C. (medium-highstringency), 65° C. (high stringency), or 70° C. (very high stringency).

For short probes that are about 15 nucleotides to about 70 nucleotidesin length, stringency conditions are defined as pre-hybridization andhybridization at about 5° C. to about 10° C. below the calculated T_(m)using the calculation according to Bolton and McCarthy (1962, Proc.Natl. Acad. Sci. USA 48: 1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6mM EDTA, 0.5% NP-40, 1×Denhardt's solution, 1 mM sodium pyrophosphate, 1mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA perml following standard Southern blotting procedures for 12 to 24 hoursoptimally. The carrier material is finally washed once in 6×SCC plus0.1% SDS for 15 minutes and twice each for 15 minutes using 6×SSC at 5°C. to 10° C. below the calculated T_(m).

The parent may be encoded by a polynucleotide with a sequence identityto the mature polypeptide coding sequence of SEQ ID NO: 1 of at least60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99%, or 100%, which encodes a polypeptide which isable to function as an albumin. In an embodiment, the parent is encodedby a polynucleotide comprising or consisting of SEQ ID NO: 1.

Albumin moiety: The albumin part of a fusion polypeptide, conjugate,associate, nanoparticle or composition comprising the albumin variant orfragment thereof according to the invention, may be referred to as an‘albumin moiety’ or ‘albumin component’. A polypeptide according to theinvention may comprise or consist of an albumin moiety.

FcRn and shFcRn: The term “FcRn” means the human neonatal Fc receptor(FcRn). shFcRn is a soluble recombinant form of FcRn. hFcRn is aheterodimer of SEQ ID NO: 30 (truncated heavy chain of the majorhistocompatibility complex class I-like Fc receptor (FCGRT)) and SEQ IDNO: 31 (beta-2-microglobulin). Together, SEQ ID NO: 30 and 31 formhFcRn.

Isolated variant: The term “isolated variant” means a variant that ismodified by the hand of man and separated completely or partially fromat least one component with which it naturally occurs. The term“isolated variant” means a variant in a form or environment which doesnot occur in nature. Non-limiting examples of isolated substancesinclude (1) any non-naturally occurring variant, (2) any variant that isat least partially removed from one or more (several) or all of thenaturally occurring constituents with which it is associated in nature;(3) any variant modified by the hand of man relative to the polypeptidefrom which it is derived (e.g. the polypeptide from which it is derivedas found in nature); or (4) any variant modified by increasing theamount of the variant e relative to other components with which it isnaturally associated (e.g., multiple copies of a gene encoding thesubstance; use of a stronger promoter than the promoter naturallyassociated with the gene encoding the substance). An isolated variantmay be present in a fermentation broth sample. The variant may be atleast 1% pure, e.g., at least 5% pure, at least 10% pure, at least 20%pure, at least 40% pure, at least 60% pure, at least 80% pure, and atleast 90% pure, as determined by SDS-PAGE or GP-HPLC.

Substantially pure variant: The term “substantially pure variant” meansa preparation that contains at most 10%, at most 8%, at most 6%, at most5%, at most 4%, at most 3%, at most 2%, at most 1%, and at most 0.5% byweight of other polypeptide material with which it is natively orrecombinantly associated. Preferably, the variant is at least 92% pure,e.g., at least 94% pure, at least 95% pure, at least 96% pure, at least97% pure, at least 98% pure, at least 99%, at least 99.5% pure, and 100%pure by weight of the total polypeptide material present in thepreparation. Purity may be determined by SDS-PAGE or GP-HPLC. Thevariants of the invention are preferably in a substantially pure form.This can be accomplished, for example, by preparing the variant bywell-known recombinant methods and by purification methods.

Mature polypeptide: The term “mature polypeptide” means a polypeptide inits final form following translation and any post-translationalmodifications, such as N-terminal processing, C-terminal truncation,glycosylation, phosphorylation, etc. The mature polypeptide may be aminoacids 1 to 585 of SEQ ID NO: 2, e.g. with alterations according to theinvention and/or with the inclusion of any post-translationalmodifications.

Mature polypeptide coding sequence: The term “mature polypeptide codingsequence” means a polynucleotide that encodes a mature albuminpolypeptide. The mature polypeptide coding sequence may be nucleotides 1to 1758 of SEQ ID NO: 1 e.g. with inclusions required to encode avariant according to the invention.

Sequence Identity: The relatedness between two amino acid sequences orbetween two nucleotide sequences is described by the parameter “sequenceidentity”.

For purposes of the invention, the degree of sequence identity betweentwo amino acid sequences is determined using the Needleman-Wunschalgorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) asimplemented in the Needle program of the EMBOSS package (EMBOSS: TheEuropean Molecular Biology Open Software Suite, Rice et al., 2000,Trends Genet. 16: 276-277), preferably version 3.0.0 or later, morepreferably version 5.0.0 or later. The optional parameters used are gapopen penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62(EMBOSS version of BLOSUM62) substitution matrix. The output of Needlelabelled “longest identity” (obtained using the -nobrief option) is usedas the percent identity and is calculated as follows:

(Identical Residues×100)/(Length of Alignment−Total Number of Gaps inAlignment)

For purposes of the invention, the degree of sequence identity betweentwo deoxyribonucleotide sequences is determined using theNeedleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) asimplemented in the Needle program of the EMBOSS package (EMBOSS: TheEuropean Molecular Biology Open Software Suite, Rice et al., 2000,supra), preferably version 3.0.0 or later, more preferably version 5.0.0or later. The optional parameters used are gap open penalty of 10, gapextension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBINUC4.4) substitution matrix. The output of Needle labelled “longestidentity” (obtained using the -nobrief option) is used as the percentidentity and is calculated as follows:

(Identical Deoxyribonucleotides×100)/(Length of Alignment−Total Numberof Gaps in Alignment)

Fragment: The term “fragment” means a polypeptide having one or more(several) amino acids deleted from the amino and/or carboxyl terminus ofan albumin and/or an internal region of albumin that has retained theability to bind to FcRn. Fragments may consist of one uninterruptedsequence derived from HSA or it may comprise two or more (several)sequences derived from HSA. The fragments according to the inventionhave a size of more than approximately 20 amino acid residues,preferably more than 30 amino acid residues, more preferred more than 40amino acid residues, more preferred more than 50 amino acid residues,more preferred more than 75 amino acid residues, more preferred morethan 100 amino acid residues, more preferred more than 200 amino acidresidues, more preferred more than 300 amino acid residues, even morepreferred more than 400 amino acid residues and most preferred more than500 amino acid residues. A fragment may comprise or consist of one moredomains of albumin such as DI+DII, DI+DIII, DII+DIII, DIII+DIII,DI+DIII+DIII, DIII+DIII+DIII, or fragments of such domains orcombinations of domains.

Domains I, II and III may be defined with reference to HSA (SEQ ID NO:2). For example, HSA domain I may consist of or comprise amino acids 1to 194 (±1 to 15 amino acids) of SEQ ID NO: 2, HSA domain II may consistof or comprise amino acids 192 (±1 to 15 amino acids) to 387 (±1 to 15amino acids) of SEQ ID NO: 2 and domain III may consist of or compriseamino acid residues 381 (±1 to 15 amino acids) to 585 (±1 to 15 aminoacids) of SEQ ID NO: 2. “±1 to 15 amino acids” means that the residuenumber may deviate by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or15 amino acids to the C-terminus and/or to the N-terminus of the statedamino acid position. Examples of domains I, II and III are described byDockal et al (The Journal of Biological Chemistry, 1999, Vol. 274(41):29303-29310) and Kjeldsen et al (Protein Expression and Purification,1998, Vol 13: 163-169) and are tabulated below.

Amino acid residues of HSA domains I, II and III with reference to SEQID NO: 2 Dockal et al Kjeldsen et al Domain I   1 to 197  1 to 192Domain II 189 to 385 193 to 382  Domain III 381 to 585 383 to 585

The skilled person can identify domains I, II and III in non-humanalbumins by amino acid sequence alignment with HSA, for example usingthe Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol.Biol. 48: 443-453) as implemented in the Needle program of the EMBOSSpackage (EMBOSS: The European Molecular Biology Open Software Suite,Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 3.0.0or later, more preferably version 5.0.0 or later. The optionalparameters used are gap open penalty of 10, gap extension penalty of0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.Other suitable software includes MUSCLE ((Multiple sequence comparisonby log-expectation, Robert C. Edgar, Version 3.6,http://www.drive5.com/muscle; Edgar (2004) Nucleic Acids Research 32(5),1792-97 and Edgar (2004) BMC Bioinformatics, 5(1):113) which may be usedwith the default settings as described in the User Guide (Version 3.6,September 2005). Versions of MUSCLE later than 3.6 may also be used forany aspect of the invention). Examples of suitable alignments areprovided in FIGS. 1 and 2.

It is preferred that domains have at least 70, 75, 80, 85, 90, 95, 96,97, 98, 99, 99.5% identity or 100% identity to Domain I, II or III ofHSA (SEQ ID NO: 2).

Allelic variant: The term “allelic variant” means any of two or more(several) alternative forms of a gene occupying the same chromosomallocus. Allelic variation arises naturally through mutation, and mayresult in polymorphism within populations. Gene mutations can be silent(no change in the encoded polypeptide) or may encode polypeptides havingaltered amino acid sequences. An allelic variant of a polypeptide is apolypeptide encoded by an allelic variant of a gene.

Coding sequence: The term “coding sequence” means a polynucleotide,which directly specifies the amino acid sequence of its translatedpolypeptide product. The boundaries of the coding sequence are generallydetermined by an open reading frame, which usually begins with the ATGstart codon or alternative start codons such as GTG and TTG and endswith a stop codon such as TAA, TAG, and TGA. The coding sequence may bea DNA, cDNA, synthetic, or recombinant polynucleotide.

cDNA: The term “cDNA” means a DNA molecule that can be prepared byreverse transcription from a mature, spliced, mRNA molecule obtainedfrom a eukaryotic cell. cDNA lacks intron sequences that may be presentin the corresponding genomic DNA. The initial, primary RNA transcript isa precursor to mRNA that is processed through a series of steps,including splicing, before appearing as mature spliced mRNA.

Nucleic acid construct: The term “nucleic acid construct” means anucleic acid molecule, either single- or double-stranded, which isisolated from a naturally occurring gene or is modified to containsegments of nucleic acids in a manner that would not otherwise exist innature or which is synthetic. The term nucleic acid construct issynonymous with the term “expression cassette” when the nucleic acidconstruct contains the control sequences required for expression of acoding sequence of the invention.

Control sequences: The term “control sequences” means all components(e.g. nucleic acid sequences) necessary for the expression of apolynucleotide encoding a variant of the invention. Each controlsequence may be native (i.e. from the same gene) or foreign (i.e. from adifferent gene) to the polynucleotide encoding the variant or native orforeign to each other. Such control sequences include, but are notlimited to, a leader, polyadenylation sequence, propeptide sequence,promoter, signal peptide sequence, and transcription terminator. At aminimum, the control sequences include a promoter, and transcriptionaland translational stop signals. The control sequences may be providedwith linkers for the purpose of introducing specific restriction sitesfacilitating ligation of the control sequences within the coding regionof the polynucleotide encoding a variant.

Operably linked: The term “operably linked” means a configuration inwhich a control sequence is placed at an appropriate position relativeto the coding sequence of a polynucleotide such that the controlsequence directs the expression of the coding sequence.

Expression: The term “expression” includes any step involved in theproduction of the variant including, but not limited to, transcription,post-transcriptional modification, translation, post-translationalmodification, and secretion.

Expression vector: The term “expression vector” means a linear orcircular DNA molecule that comprises a polynucleotide encoding a variantand is operably linked to additional nucleotides (e.g. controlsequences) that provide for its expression.

Host cell: The term “host cell” means any cell type that is susceptibleto transformation, transfection, transduction, and/or the like with anucleic acid construct or expression vector comprising a polynucleotideof the present invention. The term “host cell” encompasses any progenyof a parent cell that is not identical to the parent cell due tomutations that occur during replication.

Plasma half-life: Plasma half-life is ideally determined in vivo insuitable individuals. However, since it is time consuming and expensiveand there inevitable are ethical concerns connected with doingexperiments in animals or man it is desirable to use an in vitro assayfor determining whether plasma half-life is extended or reduced. It isknown that the binding of albumin to its receptor FcRn is important forplasma half-life and the correlation between receptor binding and plasmahalf-life is that a higher affinity of albumin to its receptor leads tolonger plasma half-life. Thus for the invention a higher affinity ofalbumin to FcRn is considered indicative of an increased plasmahalf-life and a lower affinity of albumin to its receptor is consideredindicative of a reduced plasma half-life.

In this application and claims the binding of albumin to its receptorFcRn is described using the term affinity and the expressions “stronger”or “weaker”. Thus, it should be understood that a molecule having ahigher affinity to FcRn than HSA is considered to bind stronger to FcRnthan HSA and a molecule having a lower affinity to FcRn than HSA isconsidered to bind weaker to FcRn than HSA.

The terms “longer plasma half-life” or “shorter plasma half-life” andsimilar expressions are understood to be in relationship to thecorresponding parent or reference or corresponding albumin molecule.Thus, a longer plasma half-life with respect to a variant albumin of theinvention means that the variant has longer plasma half-life than thecorresponding albumin having the same sequences except for thealteration(s) described herein, e.g. at one or more (several) positionsin Domain I and one or more (several) positions in Domain III (e.g. inSEQ ID NO: 2).

Reference: a reference is an albumin, fusion, conjugate, composition,associate or nanoparticle to which an albumin variant, fusion,conjugate, composition, associate or nanoparticle is compared. Thereference may comprise or consist of full length albumin (such as HSA ora natural allele thereof) of a fragment thereof. A reference may also bereferred to as a ‘corresponding’ albumin, fusion, conjugate,composition, associate or nanoparticle to which an albumin variant,fusion, conjugate, composition, associate or nanoparticle is compared. Areference may comprise or consist of HSA (SEQ ID NO: 2) or a fragment,fusion, conjugate, associate, nanoparticle or microparticle thereof.Preferably, the reference is identical to the polypeptide, fusionpolypeptide, conjugate, composition, associate, nanoparticle ormicroparticle according to the invention (“being studied”) with theexception of the albumin moiety. Preferably the albumin moiety of thereference comprises or consists of an albumin (e.g. HSA, SEQ ID NO: 2)or a fragment thereof. The amino acid sequence of the albumin moiety ofthe reference may be longer than, shorter than or, preferably, the same(±1 to 15 amino acids) length as the amino sequence of the albuminmoiety of the polypeptide, fusion polypeptide, conjugate, composition,associate, nanoparticle or microparticle according to the invention(“being studied”).

Equivalent amino acid positions: Throughout this specification aminoacid positions are defined in relation to full-length mature human serumalbumin (i.e. without leader sequence, SEQ ID NO: 2). However, theskilled person understands that the invention also relates to variantsof non-human albumins e.g. those disclosed herein) and/or fragments of ahuman or non-human albumin. Equivalent positions can be identified infragments of human serum albumin, in animal albumins and in fragments,fusions and other derivative or variants thereof by comparing amino acidsequences using pairwise (e.g. ClustalW) or multiple (e.g. MUSCLE)alignments. For example, FIG. 1 shows that positions equivalent to 500,550 and 573 in full length human serum albumin are easily identified infragments of human serum albumin and in albumins of other species.Positions 500, 550 and 573 are indicated by arrows. Further details areprovided in the table below.

Example of Identification of Equivalent Positions in HSA, AnimalAlbumins and Albumin Fragments

Albumin Organism Total Position equivalent to (accession Full lengthlength human serum albumin number of or Fragment of mature (native aminoacid): protein) fragment details protein 500 (K) 550 (D) 573 (K) Homosapiens Full length — 585 500 (K) 550 (D) 573 (K) (AAA98797) Homosapiens Fragment DI, DIII 399 314 (K) 364 (D) 387 (K) Homo sapiensFragment DI, DIII 403 318 (K) 368 (D) 391 (K) Macaca mulatta Full length— 584 500 (K) 550 (N) 573 (P) (NP_001182578) Rattus norvegicus Fulllength — 584 500 (K) 550 (D) 573 (P) (AAH85359) Mus musculus Full length— 584 500 (K) 550 (D) 573 (P) (AAH49971)

FIG. 1 was generated by MUSCLE using the default parameters includingoutput in ClustalW 1.81 format. The raw output data was shaded usingBoxShade 3.21 (http://www.ch.embnet.org/software/BOX_form.html) usingOutput Format: RTF_new; Font Size: 10; Consensus Line: no consensusline; Fraction of sequences (that must agree for shading): 0.5; Inputsequence format: ALN. Therefore, throughout this specification aminoacid positions defined in human serum albumin also apply to equivalentpositions in fragments, derivatives or variants and fusions of humanserum albumin, animals from other species and fragments and fusionsthereof. Such equivalent positions may have (i) a different residuenumber in its native protein and/or (ii) a different native amino acidin its native protein.

Likewise, FIG. 2 shows that equivalent positions can be identified infragments (e.g. domains) of an albumin with reference to SEQ ID NO: 2(HSA).

Conventions for Designation of Variants

For purposes of the present invention, the mature polypeptide disclosedin SEQ ID NO: 2 is used to determine the corresponding amino acidresidue in another albumin. The amino acid sequence of another albuminis aligned with the mature polypeptide disclosed in SEQ ID NO: 2, andbased on the alignment, the amino acid position number corresponding toany amino acid residue in the mature polypeptide disclosed in SEQ ID NO:2 is determined using the Needleman-Wunsch algorithm (Needleman andWunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleprogram of the EMBOSS package (EMBOSS: The European Molecular BiologyOpen Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277),preferably version 3.0.0 or later, more preferably version 5.0.0 orlater.

Identification of the corresponding amino acid residue in anotheralbumin can be determined or confirmed by an alignment of multiplepolypeptide sequences using a suitable computer program including, butnot limited to, “ClustalW” (Larkin et al., 2007, Bioinformatics 23:2947-2948), MUSCLE (multiple sequence comparison by log-expectation;version 3.5 or later; Edgar, 2004, Nucleic Acids Research 32:1792-1797), MAFFT (version 6.857 or later; Katoh and Kuma, 2002, NucleicAcids Research 30: 3059-3066; Katoh et al., 2005, Nucleic Acids Research33: 511-518; Katoh and Toh, 2007, Bioinformatics 23: 372-374; Katoh etal., 2009, Methods in Molecular Biology 537:39-64; Katoh and Toh, 2010,Bioinformatics 26: 1899-1900), and EMBOSS EMMA employing ClustalW (1.83or later; Thompson et al., 1994, Nucleic Acids Research 22: 4673-4680),using their respective default parameters.

When the other polypeptide (or protein) has diverged from the maturepolypeptide of SEQ ID NO: 2 such that traditional sequence-basedcomparison fails to detect their relationship (Lindahl and Elofsson,2000, J. Mol. Biol. 295: 613-615), other pairwise sequence comparisonalgorithms can be used. Greater sensitivity in sequence-based searchingcan be attained using search programs that utilize probabilisticrepresentations of polypeptide families (profiles) to search databases.For example, the PSI-BLAST program generates profiles through aniterative database search process and is capable of detecting remotehomologs (Atschul et al., 1997, Nucleic Acids Res. 25: 3389-3402). Evengreater sensitivity can be achieved if the family or superfamily for thepolypeptide has one or more (several) representatives in the proteinstructure databases. Programs such as GenTHREADER (Jones, 1999, J. Mol.Biol. 287: 797-815; McGuffin and Jones, 2003, Bioinformatics 19:874-881) utilize information from a variety of sources (PSI-BLAST,secondary structure prediction, structural alignment profiles, andsolvation potentials) as input to a neural network that predicts thestructural fold for a query sequence. Similarly, the method of Gough etal., 2000, J. Mol. Biol. 313: 903-919, can be used to align a sequenceof unknown structure with the superfamily models present in the SCOPdatabase. These alignments can in turn be used to generate homologymodels for the polypeptide, and such models can be assessed for accuracyusing a variety of tools developed for that purpose.

For proteins of known structure, several tools and resources areavailable for retrieving and generating structural alignments. Forexample the SCOP superfamilies of proteins have been structurallyaligned, and those alignments are accessible and downloadable. Two ormore protein structures can be aligned using a variety of algorithmssuch as the distance alignment matrix (Holm and Sander, 1998, Proteins33: 88-96) or combinatorial extension (Shindyalov and Bourne, 1998,Protein Engineering 11: 739-747), and implementation of these algorithmscan additionally be utilized to query structure databases with astructure of interest in order to discover possible structural homologs(e.g., Holm and Park, 2000, Bioinformatics 16: 566-567).

In describing the albumin variants of the present invention, thenomenclature described below is adapted for ease of reference. Theaccepted IUPAC single letter or three letter amino acid abbreviation isemployed. The term ‘point mutation’ and/or ‘alteration’ includesdeletions, insertions and substitutions.

Substitutions.

For an amino acid substitution, the following nomenclature is used:Original amino acid, position, substituted amino acid. Accordingly, forexample the substitution of threonine with alanine at position 226 isdesignated as “Thr226Ala” or “T226A”. Multiple mutations (oralterations) are separated by addition marks (“+”), e.g.,“Gly205Arg+Ser411Phe” or “G205R+S411F”, representing substitutions atpositions 205 and 411 of glycine (G) with arginine (R) and serine (S)with phenylalanine (F), respectively. The Figures also use (“/”), e.g.,“E492T/N503D” this should be viewed as interchangeable with (“+”).

Deletions.

For an amino acid deletion, the following nomenclature is used: Originalamino acid, position*. Accordingly, the deletion of glycine at position195 is designated as “Gly195*” or “G195*”. Multiple deletions areseparated by addition marks (“+”), e.g., “Gly195*+Ser411*” or“G195*+S411*”.

Insertions.

As disclosed above, an insertion may be to the N-side (‘upstream’,‘X−1’) or C-side (‘downstream’, ‘X+1’) of the amino acid occupying aposition (‘the named (or original) amino acid’, ‘X’).

For an amino acid insertion to the C-side (‘downstream’, ‘X+1’) of theoriginal amino acid (X), the following nomenclature is used: Originalamino acid, position, original amino acid, inserted amino acid.Accordingly the insertion of lysine after glycine at position 195 isdesignated “Gly195GlyLys” or “G195GK”. An insertion of multiple aminoacids is designated [Original amino acid, position, original amino acid,inserted amino acid #1, inserted amino acid #2; etc.]. For example, theinsertion of lysine and alanine after glycine at position 195 isindicated as “Gly195GlyLysAla” or “G195GKA”.

In such cases the inserted amino acid residue(s) are numbered by theaddition of lower case letters to the position number of the amino acidresidue preceding the inserted amino acid residue(s). In the aboveexample, the sequence would thus be:

Parent: Variant: 195 195 195a 195b G G - K - A

For an amino acid insertion to the N-side (‘upstream’, ‘X-1’) of theoriginal amino acid (X), the following nomenclature is used: Originalamino acid, position, inserted amino acid, original amino acid.Accordingly the insertion of lysine (K) before glycine (G) at position195 is designated “Gly195LysGly” or “G195KG”. An insertion of multipleamino acids is designated [Original amino acid, position, inserted aminoacid #1, inserted amino acid #2; etc., original amino acid]. Forexample, the insertion of lysine (K) and alanine (A) before glycine atposition 195 is indicated as “Gly195LysAlaGly” or “G195KAG”. In suchcases the inserted amino acid residue(s) are numbered by the addition oflower case letters with prime to the position number of the amino acidresidue following the inserted amino acid residue(s). In the aboveexample, the sequence would thus be:

Parent: Variant: 195 195a′ 195b′ 195 G K - A - G

Multiple Alterations.

Variants comprising multiple alterations are separated by addition marks(“+”), e.g., “Arg170Tyr+Gly195Glu” or “R170Y+G195E” representing asubstitution of tyrosine and glutamic acid for arginine and glycine atpositions 170 and 195, respectively.

Different Alterations (e.g. Substitutions).

Where different alterations (e.g. substitutions) can be introduced at aposition, the different alterations (e.g. substitutions) are separatedby a comma, e.g., “Arg170Tyr,Glu” represents a substitution of argininewith tyrosine or glutamic acid at position 170. Thus,“Tyr167Gly,Ala+Arg170Gly,Ala” designates the following variants:“Tyr167Gly+Arg170Gly”, “Tyr167Gly+Arg170Ala”, “Tyr167Ala+Arg170Gly”, and“Tyr167Ala+Arg170Ala”.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to albumin variants, comprising analteration at position in Domain I and an alteration at a position inDomain III of the mature polypeptide of SEQ ID NO: 2, or at equivalentpositions in other albumins or fragments thereof.

Variants

A first aspect of the invention provides polypeptides which are variantalbumins or fragments thereof, or fusion polypeptides comprising thevariant albumin or fragment thereof, of a parent albumin, comprising oneor more (several) alterations in Domain I of albumin, such as HSA (SEQID NO: 2) and one or more (several) alterations in Domain III ofalbumin, such as HSA (SEQ ID NO: 2).

It is preferred that the parent albumin and/or the variant albumincomprises or consists of:

(a) a polypeptide having at least 60% sequence identity to the maturepolypeptide of SEQ ID NO: 2;

(b) a polypeptide encoded by a polynucleotide that hybridizes under lowstringency conditions with (i) the mature polypeptide coding sequence ofSEQ ID NO: 1, or (ii) the full-length complement of (i);

(c) a polypeptide encoded by a polynucleotide having at least 60%identity to the mature polypeptide coding sequence of SEQ ID NO: 1;and/or

(d) a fragment of the mature polypeptide of SEQ ID NO: 2.

The variants of albumin or fragments thereof or fusion polypeptidescomprising albumin or fragments thereof comprise one or more (several)alterations, such as substitutions, deletions or insertions at positionsin Domain I and one or more (several) alterations, such assubstitutions, deletions or insertions at positions in Domain III of themature polypeptide of SEQ ID NO: 2 or in equivalent positions of otheralbumins or variants or fragments thereof. A stop codon may beintroduced in addition to the alterations described herein and ifintroduced is at position 574 or further downstream (e.g. in SEQ ID NO:2 it is introduced at from position 574 to 585).

The variant albumin, a fragment thereof, or albumin part of a fusionpolypeptide comprising variant albumin or a fragment thereof accordingto the invention has generally a sequence identity to the sequence ofHSA shown in SEQ ID NO: 2 of at least 60%, preferably at least 70%,preferably at least 80%, preferably at least 85%, preferably at least90%, more preferred at least 95%, more preferred at least 96%, morepreferred at least 97%, more preferred at least 98% and most preferredat least 99%. The variant has less than 100% identity to SEQ ID NO: 2.

The variant albumin, a fragment thereof, or albumin part of a fusionpolypeptide comprising variant albumin or a fragment thereof accordingto the invention has generally a sequence identity to the sequence ofthe parent albumin of at least 60%, preferably at least 70%, preferablyat least 80%, preferably at least 85%, preferably at least 90%, morepreferred at least 95%, more preferred at least 96%, more preferred atleast 97%, more preferred at least 98% and most preferred at least 99%.The variant has less than 100% identity to the sequence of the parentalbumin.

In one aspect, the number of alterations in the variants of theinvention is 1 to 20, e.g., 1 to 10 and 1 to 5, such as 1, 2, 3, 4, 5,6, 7, 8, 9 or 10 alterations relative to SEQ ID NO: 2 or relative to thesequence of the parent albumin.

The one or more (several) alterations in Domain I may be selected frompositions corresponding to positions from 78 to 88 (i.e. 78, 79, 80, 81,82, 83, 84, 85, 86, 87, 88) and/or from 105 to 120 (i.e. 105, 106, 107,108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120) of HSA(SEQ ID NO: 2). In HSA positions 78 to 88 form a loop and positions 105to 120 form a loop. Therefore, positions in equivalent loops of otheralbumins are also included in the invention. Preferred residues areresidues 81 to 85, particularly 82 and 83, and residues 110 to 114,particularly 111 and 112.

At position 82 of SEQ ID NO: 2 (or equivalent position of other albuminsor variants of fragments thereof), it is preferred that the alterationis a substitution, such as from the native amino acid to A, C, D, E, F,G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, more preferred to Q, D orA, even more preferred to D or A and most preferred to A. In SEQ ID NO:2 the native amino acid at position 82 is glutamic acid, therefore asubstitution to glutamic acid is not preferred.

At position 83 of SEQ ID NO: 2 (or equivalent position of other albuminsor variants of fragments thereof), it is preferred that the alterationis a substitution, such as from the native amino acid to A, C, D, E, F,G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, more preferred to N, K orS, even more preferred to N or K and most preferred to N. In SEQ ID NO:2 the native amino acid at position 82 is threonine, therefore asubstitution to threonine is not preferred.

At position 111 of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof), it is preferred that thealteration is a substitution, such as from the native amino acid to A,C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, more preferredto N, E, Q, D, G or H, even more preferred to E or Q and most preferredto E. In SEQ ID NO: 2 the native amino acid at position 111 isasparagine, therefore a substitution to asparagine is not preferred.

At position 112 of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof), it is preferred that thealteration is a substitution, such as from the native amino acid to A,C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, more preferredto F, Y or W, even more preferred to F or Y and most preferred to F. InSEQ ID NO: 2 the native amino acid at position 112 is leucine, thereforea substitution to leucine is not preferred.

At position 573 of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof), it is preferred that thealteration is a substitution, such as from the native amino acid to A,C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, more preferredto P, Y, W, H, F, T, I or V, even more preferred to P, Y or W and mostpreferred to P. In SEQ ID NO: 2 the native amino acid at position 573 islysine, therefore a substitution to lysine is not preferred.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82 and 83; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82 and 111; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82 and 112; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82 and 573; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 83 and 111; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 83 and 112; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 83 and 573; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 111 and 112; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 111 and 573; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 112 and 573; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82, 83, and 111; of SEQ ID NO: 2 (or equivalent position ofother albumins or variants of fragments thereof) of an albumin, variantor fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82, 83, 112; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82, 83, and 573; of SEQ ID NO: 2 (or equivalent position ofother albumins or variants of fragments thereof) of an albumin, variantor fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82, 111, and 112; of SEQ ID NO: 2 (or equivalent position ofother albumins or variants of fragments thereof) of an albumin, variantor fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82, 111, and 573; of SEQ ID NO: 2 (or equivalent position ofother albumins or variants of fragments thereof) of an albumin, variantor fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82, 112, and 573; of SEQ ID NO: 2 (or equivalent position ofother albumins or variants of fragments thereof) of an albumin, variantor fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 83, 111, and 112; of SEQ ID NO: 2 (or equivalent position ofother albumins or variants of fragments thereof) of an albumin, variantor fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 83, 111, and 573; of SEQ ID NO: 2 (or equivalent position ofother albumins or variants of fragments thereof) of an albumin, variantor fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 83, 112, and 573; of SEQ ID NO: 2 (or equivalent position ofother albumins or variants of fragments thereof) of an albumin, variantor fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 111, 112, and 573; of SEQ ID NO: 2 (or equivalent position ofother albumins or variants of fragments thereof) of an albumin, variantor fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82, 83, 111, and 112; of SEQ ID NO: 2 (or equivalent positionof other albumins or variants of fragments thereof) of an albumin,variant or fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82, 83, 111, and 573; of SEQ ID NO: 2 (or equivalent positionof other albumins or variants of fragments thereof) of an albumin,variant or fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82, 83, 112, and 573; of SEQ ID NO: 2 (or equivalent positionof other albumins or variants of fragments thereof) of an albumin,variant or fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82, 111, 112, and 573; of SEQ ID NO: 2 (or equivalent positionof other albumins or variants of fragments thereof) of an albumin,variant or fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 83, 111, 112, and 573; of SEQ ID NO: 2 (or equivalent positionof other albumins or variants of fragments thereof) of an albumin,variant or fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 82, 83, 111, 112, and 573; of SEQ ID NO: 2 (or equivalentposition of other albumins or variants of fragments thereof) of analbumin, variant or fragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 425 and 573; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 505 and 573; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 527 and 573; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

An albumin variant may comprise alterations, e.g. substitutions, atpositions 534 and 573; of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof) of an albumin, variant orfragment thereof, especially SEQ ID NO: 2.

Particularly preferred albumin variants comprise substitutionsT83N/N111E (e.g. SEQ ID NO: 32); T83N/N111E/K573P (e.g. SEQ ID NO: 33);T83N/K573P (e.g. SEQ ID NO: 34); T83K/K573P (e.g. SEQ ID NO: 38);E82A/K573P (e.g. SEQ ID NO: 39); L112F/K573P (e.g. SEQ ID NO: 40);E82D/K573P (e.g. SEQ ID NO: 43); P110G/K573P (e.g. SEQ ID NO: 44);N111D/K573P (e.g. SEQ ID NO: 60); N111G/K573P (e.g. SEQ ID NO: 61);N111H/K573P (e.g. SEQ ID NO: 62); E425A/K573P (e.g. SEQ ID NO: 64);E505Q/K573P (e.g. SEQ ID NO: 65); T527M/K573P (e.g. SEQ ID NO: 66);N111E/K573P (e.g. SEQ ID NO: 68); K534V/K573P (e.g. SEQ ID NO: 73);N111Q/K573P (e.g. SEQ ID NO: 74) which are descried with reference toHSA (SEQ ID NO: 2). Other preferred albumin variants comprise equivalentsubstitutions in albumins other than HSA (SEQ ID NO: 2).

Also, an albumin variant according to the invention may comprise one ormore (several) alterations at positions selected from 78 to 88 (78, 79,80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91) and/or 105 to 120 (105,106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119,120) and/or 425, 505, 510, 512, 524, 527, 531, 534, 569, 575 of HSA (SEQID NO: 2) or equivalent positions of other albumins. Preferredalterations are substitutions such as those described for thesepositions in the first aspect of the invention. Particularly preferredsubstitutions include D108A (SEQ ID NO: 59); D108E (e.g. SEQ ID NO: 70);N109K (e.g. SEQ ID NO: 69); P110G (e.g. SEQ ID NO: 42); N111D (e.g. SEQID NO: 46); N111E (e.g. SEQ ID NO: 67); N111G (e.g. SEQ ID NO: 48);N111H (e.g. SEQ ID NO: 49); N111K (e.g. SEQ ID NO: 54); L112F (e.g. SEQID NO: 37); E425A (e.g. SEQ ID NO: 63); E425K (e.g. SEQ ID NO: 55);E505Q (e.g. SEQ ID NO: 45); H510D (e.g. SEQ ID NO: 57); D512E (e.g. SEQID NO: 50); K524A (e.g. SEQ ID NO: 51); T527A (e.g. SEQ ID NO: 52);T527M (e.g. SEQ ID NO: 47); E531H (e.g. SEQ ID NO: 53); K534V (e.g. SEQID NO: 56); A569S (e.g. SEQ ID NO: 58); L575F (e.g. SEQ ID NO: 72); E82A(e.g. SEQ ID NO: 36); E82D (e.g. SEQ ID NO: 41); T83K (e.g. SEQ ID NO:35); T83N (e.g. SEQ ID NO: 71) which are descried with reference to HSA(SEQ ID NO: 2). Other preferred albumin variants comprising one or more(several) alterations may comprise equivalent substitutions in albuminsother than HSA (SEQ ID NO: 2).

It is preferred that the variant albumin, a fragment thereof or fusionpolypeptide comprising the variant albumin or fragment thereof hasaltered binding affinity to FcRn and/or an altered plasma half-lifecompared with the corresponding parent or reference albumin, fragmentthereof, or fusion polypeptide comprising the variant albumin orfragment thereof and/or an altered binding affinity to FcRn.

In a particularly preferred embodiment the parent or reference albuminis HSA (SEQ ID NO: 2) and the variant albumin, a fragment thereof orfusion polypeptide comprising the variant albumin or fragment thereofhas altered binding affinity to FcRn and/or an altered plasma half-lifecompared with the HSA, the corresponding fragment or fusion polypeptidecomprising HSA or fragment thereof and/or an altered binding affinity toFcRn.

The correlation between binding of albumin to its receptor and plasmahalf-life has been realized by the present inventors based on thenatural occurring allele of HSA D494N. The inventors have previouslyanalyzed this allele and found that it has a lower affinity to itsreceptor FcRn than the affinity of WT HSA to FcRn.

Further, it has been disclosed that a transgenic mouse having thenatural mouse FcRn replaced with human FcRn has a higher serum albuminlevel than normal mouse (J Exp Med. (2003) 197(3):315-22). The inventorshave previously discovered that human FcRn has a higher affinity tomouse serum albumin than mouse FcRn has to mouse serum albumin and,therefore, the observed increase in serum albumin in the transgenic micecorresponds with a higher affinity between serum albumin and itsreceptor, confirming the correlation between albumin binding to FcRn andplasma half-life. In addition, variants of albumin that have little orno binding to FcRn have been shown to have reduced half-life in a mousemodel, Kenanova et al (2009) J. Nucl. Med.; 50 (Supplement 2):1582).

One way to determine whether the affinity of a variant albumin to FcRnis higher or lower than the parent or reference albumin is to use theSurface Plasmon Resonance assay (SPR) as described below. The skilledperson will understand that other methods might be useful to determinewhether the affinity of a variant albumin to FcRn is higher or lowerthan the affinity of the parent or reference albumin to FcRn, e.g.,determination and comparison of the binding constants KD. The bindingaffinity (KD) between a first molecule (e.g. ligand) and a secondmolecule (e.g. receptor) is a function of the kinetic constants forassociation (on rate, k_(a)) and dissociation (off-rate, k_(d))according to KD=k_(d)/k_(a). Thus, according to the invention variantalbumins having a KD that is lower than the KD for natural HSA isconsidered to have a higher plasma half-life than HSA and variantalbumins having a KD that is higher than the KD for natural HSA isconsidered to have a lower plasma half-life than HSA.

In an embodiment of the invention, the variants of albumin or fragmentsthereof, or fusion polypeptides comprising variant albumin or a fragmentthereof according to the invention have a plasma half-life that islonger than the plasma half-life of the parent or reference albuminfragment thereof or fusion polypeptide comprising the parent orreference albumin or a fragment thereof and/or an stronger bindingaffinity to FcRn.

In a further embodiment the variants of albumin or fragments thereof, orfusion polypeptides comprising variant albumin or fragments thereofaccording to the invention have a plasma half-life that is shorter thanthe plasma half-life of the parent or reference albumin fragment thereofor fusion polypeptide comprising the parent or reference albumin or afragment thereof and/or an weaker binding affinity to FcRn.

In addition to alterations at positions in Domains I (such as withinloop 78 to 88 and/or within loop 105 to 120 as described herein) and III(or equivalent position of other albumins or variants of fragmentsthereof) the variant albumin or fragments thereof, or fusionpolypeptides comprising variant albumin or fragments thereof accordingto the invention may contain additional substitutions, deletions orinsertions in other positions of the molecules. Such additionalsubstitutions, deletions or insertions may be useful in order to alterother properties of the molecules such as but not limited to alteredglycosylation; introduction of reactive groups of the surface such athiol groups, removing/generating a carbamoylation site; etc.

Residues that might be altered in order to provide reactive residues onthe surface and which advantageously could be applied to the inventionhas been disclosed in WO2010/092135 (incorporated herein by reference).Particular preferred residues include the positions corresponding topositions in SEQ ID NO: 2.

As examples of alterations that can be made in SEQ ID NO: 2 or incorresponding positions in other albumins in order to provide a reactivethiol group on the surface includes alterations corresponding tofollowing alterations in SEQ ID NO: 2: L585C, D1C, A2C, D562C, A364C,A504C, E505C, T79C, E86C, D129C, D549C, A581C, D121C, E82C, S270C,A578C, L595LC, D1DC, A2AC, D562DC, A364AC, A504AC, E505EC, T79TC, E86EC,D129DC, D549DC, A581AC, A581AC, D121DC, E82EC, S270SC, S579AC, C360*,C316*, C75*, 0168*, C558*, 0361*, 091*, C124*, C169* and C567*.Alternatively a cysteine residue may be added to the N or C terminal ofalbumin. The term ‘reactive thiol’ means and/or includes a thiol groupprovided by a Cys which is not disulphide bonded to a Cysteine and/orwhich is sterically available for binding to a partner such as aconjugation partner.

Fusion Polypeptides

A second aspect of the invention relates to fusion polypeptides.Therefore, the variants of albumin or fragments thereof according to theinvention may be fused with a non-albumin polypeptide fusion partner.The fusion partner may in principle be any polypeptide but generally itis preferred that the fusion partner is a polypeptide havingtherapeutic, prophylactic (including vaccine), diagnostic, imaging orother beneficial properties. Such properties may be referred to as‘pharmaceutically beneficial properties’. Fusion polypeptides comprisingalbumin or fragments thereof are known in the art. It has been foundthat such fusion polypeptides comprising albumin or a fragment thereofand a fusion partner polypeptide have a longer plasma half-life comparedto the unfused fusion partner polypeptide alone. According to theinvention it is possible to alter the plasma half-life of the fusionpolypeptides according to the invention compared to the correspondingfusion polypeptides of the prior art. ‘Alter’ includes both increasingthe plasma half-life and decreasing the plasma half-life. Increasing theplasma half-life is preferred. The invention allows tailoring ofhalf-life to a term desired.

One or more (several) therapeutic, prophylactic (including vaccine),diagnostic, imaging or other beneficial may be fused to the N-terminus,the C-terminus of albumin, inserted into a loop in the albumin structureor any combination thereof. It may or it may not comprise linkersequences separating the various components of the fusion polypeptide.

Teachings relating to fusions of albumin or a fragment thereof are knownin the art and the skilled person will appreciate that such teachingscan also be applied to the invention. WO 2001/79271A (particularly page9 and/or Table 1), WO 2003/59934 (particularly Table 1), WO03/060071(particularly Table 1) and WO01/079480 (particularly Table 1) (eachincorporated herein by reference in their entirety) also containexamples of therapeutic, prophylactic (including vaccine), diagnostic,imaging or other beneficial polypeptides that may be fused to albumin orfragments thereof, and these examples apply also to the invention.

Further preferences for the second aspect of the invention include thoseof the first aspect of the invention and those provided below thetwelfth aspect of the invention. The skilled person understands that anyaspect of the invention may be combined with another aspect or aspectsof the invention and/or with one or more (several) of the preferencesfor the aspects of the invention and/or other disclosures made herein.

Polynucleotides

A third aspect of the invention relates to isolated polynucleotides thatencode any of the variants or fusion polypeptides of the invention. Thepolynucleotide may be an isolated polynucleotide. The polynucleotide maybe comprised a in a vector (such as a plasmid) and/or in a host cell.

Further preferences for the third aspect of the invention include thoseof the first aspect of the invention and those provided below thetwelfth aspect of the invention. The skilled person understands that anyaspect of the invention may be combined with another aspect or aspectsof the invention and/or with one or more (several) of the preferencesfor the aspects of the invention and/or other disclosures made herein.

Nucleic Acid Constructs

A fourth aspect of the invention relates to nucleic acid constructscomprising a polynucleotide encoding a variant or fusion polypeptide ofthe invention operably linked to one or more (several) control sequencesthat direct the expression of the coding sequence in a suitable hostcell under conditions compatible with the control sequences.

A polynucleotide may be manipulated in a variety of ways to provide forexpression of a variant. Manipulation of the polynucleotide prior to itsinsertion into a vector may be desirable or necessary depending on theexpression vector. The techniques for modifying polynucleotidesutilizing recombinant DNA methods are well known in the art.

The control sequence may be a promoter sequence, which is recognized bya host cell for expression of the polynucleotide. The promoter sequencecontains transcriptional control sequences that mediate the expressionof the variant. The promoter may be any nucleic acid sequence that showstranscriptional activity in the host cell including mutant, truncated,and hybrid promoters, and may be obtained from genes encodingextracellular or intracellular polypeptides either homologous orheterologous to the host cell.

In a yeast host, useful promoters are obtained from the genes forSaccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiaeprotease A (PRA1), Saccharomyces cerevisiae protease B (PRB1),Saccharomyces cerevisiae translation elongation factor (TEF1),Saccharomyces cerevisiae translation elongation factor (TEF2),Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces cerevisiaealcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH1,ADH2/GAP), Saccharomyces cerevisiae triose phosphate isomerase (TPI),Saccharomyces cerevisiae metallothionein (CUP1), and Saccharomycescerevisiae 3-phosphoglycerate kinase. Other useful promoters for yeasthost cells are described by Romanos et al., 1992, Yeast 8: 423-488.

The skilled person knows useful promoters for use in rice and mammaliancells, such as CHO or HEK. In a rice host, useful promoters are obtainedfrom cauliflower mosaic virus 35S RNA gene (CaMV35S), maize alcoholdehydrogenase (Adh1) and alpha Amy3.

In a mammalian host cell, such as CHO or HEK, useful promoters areobtained from Cytomegalovirus (CMV) and CAG hybrid promoter (hybrid ofCMV early enhancer element and chicken beta-actin promoter), Simianvacuolating virus 40 (SV40).

The control sequence may also be a suitable transcription terminatorsequence, which is recognized by a host cell to terminate transcription.The terminator sequence is operably linked to the 3′-terminus of thepolynucleotide encoding the variant. Any terminator that is functionalin the host cell may be used.

Preferred terminators for yeast host cells are obtained from the genesfor Saccharomyces cerevisiae enolase, Saccharomyces cerevisiaecytochrome C (CYC1), Saccharomyces cerevisiae alcohol dehydrogenase(ADH1) and Saccharomyces cerevisiae glyceraldehyde-3-phosphatedehydrogenase. Other useful terminators for yeast host cells aredescribed by Romanos et al., 1992, supra. The skilled person knowsuseful terminators for use in rice and mammalian cells, such as CHO orHEK. For example, in a rice host, preferred terminators are obtainedfrom Agrobacterium tumefaciens nopaline synthase (Nos) and cauliflowermosaic virus 35S RNA gene (CaMV35S)

The control sequence may also be a suitable leader sequence, anontranslated region of an mRNA that is important for translation by thehost cell. The leader sequence is operably linked to the 5′-terminus ofthe polynucleotide encoding the variant. Any leader sequence that isfunctional in the host cell may be used.

Suitable leaders for yeast host cells are obtained from the genes forSaccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha-factor, andSaccharomyces cerevisiae alcoholdehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

The control sequence may also be a polyadenylation sequence, a sequenceoperably linked to the 3′-terminus of the variant-encoding sequence and,when transcribed, is recognized by the host cell as a signal to addpolyadenosine residues to transcribed mRNA. Any polyadenylation sequencethat is functional in the host cell may be used.

Useful polyadenylation sequences for yeast host cells are described byGuo and Sherman, 1995, Mol. Cellular Biol. 15: 5983-5990.

The control sequence may also be a signal peptide coding region thatencodes a signal peptide linked to the N-terminus of a variant anddirects the variant into the cell's secretory pathway. The 5′-end of thecoding sequence of the polynucleotide may inherently contain a signalpeptide coding region naturally linked in translation reading frame withthe segment of the coding region that encodes the variant.Alternatively, the 5′-end of the coding sequence may contain a signalpeptide coding region that is foreign to the coding sequence. Theforeign signal peptide coding region may be required where the codingsequence does not naturally contain a signal peptide coding region.Alternatively, the foreign signal peptide coding region may simplyreplace the natural signal peptide coding region in order to enhancesecretion of the variant. However, any signal peptide coding region thatdirects the expressed variant into the secretory pathway of a host cellmay be used.

Useful signal peptides for yeast host cells are obtained from the genesfor Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiaeinvertase. Other useful signal peptide coding sequences are described byRomanos et al., 1992, supra. The skilled person knows useful signalpeptides for use in rice and mammalian cells, such as CHO or HEK.

Where both signal peptide and propeptide regions are present at theN-terminus of a variant, the propeptide region is positioned next to theN-terminus of the variant and the signal peptide region is positionednext to the N-terminus of the propeptide region.

Further preferences for the fourth aspect of the invention include thoseof the first aspect of the invention and those provided below thetwelfth aspect of the invention. The skilled person understands that anyaspect of the invention may be combined with another aspect or aspectsof the invention and/or with one or more (several) of the preferencesfor the aspects of the invention and/or other disclosures made herein.

Preparation of Variants

A fifth aspect of the invention relates to a method for preparing orobtaining a variant albumin or fragment thereof, or fusion polypeptidescomprising the variant albumin or fragments thereof, or associates ofvariant albumin or fragment thereof comprising:

(a) introducing into a parent albumin or fragments thereof, or fusionpolypeptides comprising the parent albumin or fragments thereof one ormore (several) alterations in Domain I and one or more (several)alterations in Domain III; and

(b) recovering the variant albumin or fragment thereof, or fusionpolypeptides comprising the variant albumin or fragment thereof.

Preferred alterations are as described in relation to the first aspectof the invention. The resultant variant albumin or fragment thereof mayhave altered FcRn-binding affinity compared to the FcRn-binding affinityof a reference such as a parent albumin or fragment which does notcomprise the alterations. More preferably, the resultant variant albuminor fragment thereof has a stronger FcRn-binding affinity.

The invention includes a method for preparing a polypeptide which is avariant of albumin, fragment thereof or fusion polypeptide comprisingsaid variant albumin or fragment thereof having a binding affinity toFcRn which is altered compared to the binding affinity of a referencealbumin, fragment or fusion thereof to FcRn, comprising:

(a) providing a nucleic acid encoding a parent albumin such as analbumin having at least 60% sequence identity to SEQ ID NO: 2;

(b) modifying the sequence of step (a), to encode a polypeptide which isa variant albumin, fragment thereof or fusion polypeptide comprisingsaid variant albumin or fragment thereof comprising:

(i) alterations at positions corresponding to one or more (several)positions in Domain I of the parent albumin and one or more (several)positions in Domain III (Domain 3), or

(ii) alterations at positions corresponding to one of more (several) ofany of positions 78 to 120 of Domain I of SEQ ID NO: 2 or at positionscorresponding to one or more (several) of any of positions 425, 505,510, 512, 524, 527, 531, 534, 569, 573, 575 of Domain III of SEQ ID NO:2;

(c) optionally, introducing the modified sequence of step (b) in asuitable host cell;

(d) optionally, growing the cells in a suitable growth medium undercondition leading to expression of the polypeptide; and

(e) optionally, recovering the polypeptide from the growth medium;

-   -   wherein the polypeptide has an altered binding affinity to FcRn        and/or an altered plasma half-life compared with the half-life        of a parent albumin, reference albumin, fragment thereof or        fusion polypeptide comprising said parent albumin, reference        albumin or fragment or fusion thereof.

It is preferred that the parent albumin and/or the variant albumincomprises or consists of:

(a) a polypeptide having at least 60% sequence identity to the maturepolypeptide of SEQ ID NO: 2;

(b) a polypeptide encoded by a polynucleotide that hybridizes under lowstringency conditions with (i) the mature polypeptide coding sequence ofSEQ ID NO: 1, or (ii) the full-length complement of (i);

(c) a polypeptide encoded by a polynucleotide having at least 60%identity to the mature polypeptide coding sequence of SEQ ID NO: 1;and/or

(d) a fragment of the mature polypeptide of SEQ ID NO: 2.

The variants can be prepared by those skilled persons using anymutagenesis procedure known in the art, such as site-directedmutagenesis, synthetic gene construction, semi-synthetic geneconstruction, random mutagenesis, shuffling, etc.

Site-directed mutagenesis is a technique in which one or more (several)mutations (alterations) are created at one or more (several) definedsites in a polynucleotide encoding the parent.

Site-directed mutagenesis can be accomplished in vitro by PCR involvingthe use of oligonucleotide primers containing the desired mutation.Site-directed mutagenesis can also be performed in vitro by cassettemutagenesis involving the cleavage by a restriction enzyme at a site inthe plasmid comprising a polynucleotide encoding the parent andsubsequent ligation of an oligonucleotide containing the mutation in thepolynucleotide. Usually the restriction enzyme that digests at theplasmid and the oligonucleotide is the same, permitting ligation of theplasmid and insert to one another. See, e.g., Scherer and Davis, 1979,Proc. Natl. Acad. Sci. USA 76: 4949-4955; and Barton et al., 1990,Nucleic Acids Res. 18: 7349-4966.

Site-directed mutagenesis can also be accomplished in vivo by methodsknown in the art. See, e.g., U.S. Patent Application Publication NO:2004/0171154; Storici et al., 2001, Nature Biotechnol. 19: 773-776; Krenet al., 1998, Nat. Med. 4: 285-290; and Calissano and Macino, 1996,Fungal Genet. Newslett. 43: 15-16.

Any site-directed mutagenesis procedure can be used in the invention.There are many commercial kits available that can be used to preparevariants.

Synthetic gene construction entails in vitro synthesis of a designedpolynucleotide molecule to encode a polypeptide of interest. Genesynthesis can be performed utilizing a number of techniques, such as themultiplex microchip-based technology described by Tian et al. (2004,Nature 432: 1050-1054) and similar technologies wherein oligonucleotidesare synthesized and assembled upon photo-programmable microfluidicchips.

Single or multiple amino acid substitutions, deletions, and/orinsertions can be made and tested using known methods of mutagenesis,recombination, and/or shuffling, followed by a relevant screeningprocedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988,Science 241: 53-57; Bowie and Sauer, 1989, Proc. Natl. Acad. Sci. USA86: 2152-2156; WO 95/17413; or WO 95/22625. Other methods that can beused include error-prone PCR, phage display (e.g., Lowman et al., 1991,Biochemistry 30: 10832-10837; U.S. Pat. No. 5,223,409; WO 92/06204) andregion-directed mutagenesis (Derbyshire et al., 1986, Gene 46: 145; Neret al., 1988, DNA 7: 127).

Mutagenesis/shuffling methods can be combined with high-throughput,automated screening methods to detect activity of cloned, mutagenizedpolypeptides expressed by host cells (Ness et al., 1999, NatureBiotechnology 17: 893-896). Mutagenized DNA molecules that encode activepolypeptides can be recovered from the host cells and rapidly sequencedusing standard methods in the art. These methods allow the rapiddetermination of the importance of individual amino acid residues in apolypeptide.

Semi-synthetic gene construction is accomplished by combining aspects ofsynthetic gene construction, and/or site-directed mutagenesis, and/orrandom mutagenesis, and/or shuffling. Semi-synthetic construction istypified by a process utilizing polynucleotide fragments that aresynthesized, in combination with PCR techniques. Defined regions ofgenes may thus be synthesized de novo, while other regions may beamplified using site-specific mutagenic primers, while yet other regionsmay be subjected to error-prone PCR or non-error prone PCRamplification. Polynucleotide sub sequences may then be shuffled.

Further preferences for the fifth aspect of the invention include thoseof the first aspect of the invention and those provided below thetwelfth aspect of the invention. The skilled person understands that anyaspect of the invention may be combined with another aspect or aspectsof the invention and/or with one or more (several) of the preferencesfor the aspects of the invention and/or other disclosures made herein.

Methods of Production

A sixth aspect of the invention relates to methods of preparation of avariant according to the invention. The variants of the invention can beprepared using techniques well known to the skilled person. Oneconvenient way is by cloning nucleic acid encoding the parent albumin ora fragment thereof or fusion polypeptide comprising albumin or afragment thereof, modifying said nucleic acid to introduce the desiredsubstitution(s) at positions in Domain I and Domain III of the maturepolypeptide of SEQ ID NO: 2 (or equivalent positions in other albuminsor fragments thereof), preparing a suitable genetic construct where themodified nucleic acid is placed in operative connection with suitableregulatory genetic elements, such as promoter, terminator, activationsites, ribosome binding sites etc., introducing the genetic constructinto a suitable host organism, culturing the transformed host organismunder conditions leading to expression of the variant and recovering thevariant. All these techniques are known in the art and it is within theskills of the average practitioner to design a suitable method forpreparing a particular variant according to the invention.

The variant polypeptide of the invention may also be connected to asignal sequence in order to have the variant polypeptide secreted intothe growth medium during culturing of the transformed host organism. Itis generally advantageous to have the variant polypeptide secreted intothe growth medium in order to ease recovery and purification.

Techniques for preparing variant polypeptides have also been disclosedin WO 2009019314 (included by reference) and these techniques may alsobe applied to the invention.

Albumins have been successfully expressed as recombinant proteins in arange of hosts including fungi (including but not limited to Aspergillus(WO06066595), Kluyveromyces (Fleer 1991, Bio/technology 9, 968-975),Pichia (Kobayashi 1998 Therapeutic Apheresis 2, 257-262) andSaccharomyces (Sleep 1990, Bio/technology 8, 42-46)), bacteria(Pandjaitab 2000, J. Allergy Clin. Immunol. 105, 279-285)), animals(Barash 1993, Transgenic Research 2, 266-276) and plants (including butnot limited to potato and tobacco (Sijmons 1990, Bio/technology 8, 217and Farran 2002, Transgenic Research 11, 337-346) and rice e.g. Oryzasativa) and mammalian cells such as CHO and HEK. The variant polypeptideof the invention is preferably produced recombinantly in a suitable hostcell. In principle any host cell capable of producing a polypeptide insuitable amounts may be used and it is within the skills of the averagepractitioner to select a suitable host cell according to the invention.A preferred host organism is yeast, preferably selected amongSaccharomycacae, more preferred Saccharomyces cerevisiae.

The variant polypeptides of the invention may be recovered and purifiedfrom the growth medium using a combination of known separationtechniques such as filtration, centrifugation, chromatography, andaffinity separation techniques etc. It is within the skills of theaverage practitioner to purify the variants of the invention using aparticular combination of such known separation steps. As an example ofpurification techniques that may be applied to the variants of theinvention can be mentioned the teaching of WO00/44772.

The variant polypeptides of the invention may be used for delivering atherapeutically beneficial compound (including prophylacticallybeneficial compound such as a vaccine) to an animal or a humanindividual in need thereof. Such therapeutically beneficial compoundsinclude, but are not limited, to labels and readily detectable compoundsfor use in diagnostics, such as various imaging techniques;pharmaceutical active compounds such as drugs, or specifically bindingmoieties such as antibodies. The variants of the invention may even beconnected to two or more (several) different therapeutically beneficialcompounds, e.g., an antibody and a drug, which gives the combinedmolecule the ability to bind specifically to a desired target andthereby provide a high concentration of the connected drug at thatparticular target.

Further preferences for the sixth aspect of the invention include thoseof the first aspect of the invention and those provided below thetwelfth aspect of the invention. The skilled person understands that anyaspect of the invention may be combined with another aspect or aspectsof the invention and/or with one or more (several) of the preferencesfor the aspects of the invention and/or other disclosures made herein.

Conjugates

A seventh aspect of the invention relates to conjugates (conjugations).Therefore, the variants of albumin or fragments thereof or fusionpolypeptides according to the invention may be conjugated to a secondmolecule (‘conjugation partner’) using techniques known within the art.The conjugation partner may be a therapeutic, prophylactic (includingvaccine), diagnostic, imaging or other beneficial moiety. Saidconjugation partner may be a polypeptide or a non-polypeptide chemical.The conjugation partner may be a polypeptide, a chemical (e.g.chemically synthesized drug) or a nucleic acid (e.g. DNA, RNA, siRNA).

Said second molecule may comprise a diagnostic or imaging moiety, and inthis embodiment the conjugate may be useful as a diagnostic tool such asin imaging; or the second molecule may be a therapeutic or prophylactic(e.g. vaccine) compound and in this embodiment the conjugate may be usedfor therapeutic or prophylactic (e.g. vaccination) purposes where theconjugate will have the therapeutic or prophylactic properties of thetherapeutic or prophylactic compound as well as the desirable plasmahalf-life provided by the albumin part of the conjugate. Conjugates ofalbumin and a therapeutic molecule are known in the art and it has beenverified that such conjugates have long plasma half-life compared withthe non-conjugated, free therapeutic molecule as such. According to theinvention it is possible to alter the binding affinity to FcRn and/orplasma half-life of the conjugate according to the invention compared tothe corresponding conjugates of the prior art. ‘Alter’ includes bothincreasing the plasma half-life and decreasing the plasma half-lifebinding affinity to FcRn and/or increasing the binding affinity anddecreasing the binding affinity to FcRn. Increasing the plasma half-lifeand/or binding affinity to FcRn is preferred. The conjugates mayconveniently be linked viaa free thiol group present on the surface ofHSA (amino acid residue 34 of mature HSA) using well known chemistry.

In one particular preferred aspect the variant albumin or fragmentthereof is conjugated to a beneficial therapeutic or prophylactic(including vaccine) compound and the conjugate is used for treatment ofa condition in a patient in need thereof, which condition is responsiveto the particular selected therapeutic compound. Techniques forconjugating such a therapeutically useful compound to the variantalbumin or fragment thereof are known in the art. WO 2009/019314(incorporated herein by reference in its entirety) discloses examples oftechniques suitable for conjugating a therapeutically compound to apolypeptide which techniques can also be applied to the invention.Further WO 2009/019314 discloses examples of compounds and moieties thatmay be conjugated to substituted transferrin and these examples may alsobe applied to the invention. The teaching of WO 2009/019314 is includedherein by reference.

HSA contains in its natural form one free thiol group (at Cys34) thatconveniently may be used for conjugation. As a particular embodimentwithin this aspect the variant albumin or fragment thereof may comprisefurther modifications provided to generate additional free thiol groupson the surface. This has the benefit that the payload of the variantalbumin or fragment thereof is increased so that more than one moleculeof the therapeutic (e.g. prophylactic) compound can be conjugated toeach molecule of variant albumin or fragment thereof, or two or more(several) different therapeutic compounds may be conjugated to eachmolecule of variant albumin or fragment thereof, e.g., a compound havingtargeting properties such as an antibody specific for example a tumor;and a cytotoxic drug conjugated to the variant albumin or fragmentthereof thereby creating a highly specific drug against a tumor.Teaching of particular residues that may be modified to provide forfurther free thiol groups on the surface can be found in co-pendingpatent application WO 2010/092135, which is incorporated by reference.

The conjugation partner may alternatively be conjugated to a fusionpolypeptide (described herein), resulting in a molecule comprising afusion partner fused to the albumin as well as a conjugation partnerconjugated to the same albumin or even to the fusion partner.

Further preferences for the seventh aspect of the invention includethose of the first aspect of the invention and those provided below thetwelfth aspect of the invention. The skilled person understands that anyaspect of the invention may be combined with another aspect or aspectsof the invention and/or with one or more (several) of the preferencesfor the aspects of the invention and/or other disclosures made herein.

Associates

An eighth aspect of the invention relates to associates. Therefore, thevariants of albumin or fragments thereof or fusion polypeptides mayfurther be used in form of “associates”. In this connection the term“associate” is intended to mean a compound comprising a variant ofalbumin or a fragment thereof and another compound bound or associatedto the variant albumin or fragment thereof by non-covalent binding. Asan example of such an associate can be mentioned an associate consistingvariant albumin and a lipid associated to albumin by a hydrophobicinteraction. Such associates are known in the art and they may beprepared using well known techniques. As an example of a preferredassociate according to the invention, can be mentioned an associatecomprising variant albumin and a taxane, a taxol or taxol derivative(e.g. paclitaxel). Further examples of associates comprise atherapeutic, prophylactic (including vaccine), diagnostic, imaging orother beneficial moiety.

The half-life of an albumin associate according to the invention may belonger or shorter than the half-life of the ‘other compound’ alone. Thehalf-life of an albumin associate according to the invention may belonger or shorter than the half-life of the analogous/equivalent albuminassociate comprising or consisting of a reference albumin such as nativeHSA (instead of an albumin variant or derivative according to theinvention) and the ‘other compound’. Likewise, the binding affinity toFcRn an albumin associate according to the invention may be stronger orweaker than the binding affinity to FcRn of the analogous/equivalentalbumin associate comprising or consisting of a reference albumin suchas native HSA (instead of an albumin variant or derivative according tothe invention) and the ‘other compound’. Methods for the preparation ofassociates are well-known to the skilled person, for example,formulation (by association) of HSA with Lipo-compounds is described inHussain, R. and Siligardi, G. (2006) International Journal of PeptideResearch and Therapeutics, Vol. 12, NO: 3, pp. 311-315.

Further preferences for the eighth aspect of the invention include thoseof the first aspect of the invention and those provided below thetwelfth aspect of the invention. The skilled person understands that anyaspect of the invention may be combined with another aspect or aspectsof the invention and/or with one or more (several) of the preferencesfor the aspects of the invention and/or other disclosures made herein.

Compositions

A ninth aspect of the invention relates to compositions. Therefore theinvention is also directed to the use of a variant of albumin or afragment thereof or fusion polypeptides comprising variant albumin orfragments thereof, or a conjugate comprising a variant of albumin or afragment thereof, or an associate comprising a variant of albumin or afragment thereof for the manufacture of a pharmaceutical composition,wherein the variant of albumin or a fragment thereof or fusionpolypeptides comprising variant albumin or fragments thereof, or aconjugate comprising a variant of albumin or a fragment thereof, or anassociate comprising a variant of albumin or a fragment thereof has analtered binding affinity to FcRn and/or an altered plasma half-lifecompared with HSA or the corresponding fragment thereof or fusionpolypeptide comprising HSA or fragment thereof or conjugate comprisingHSA.

In this connection the corresponding fragment of HSA is intended to meana fragment of HSA that aligns with and has same number of amino acids asthe fragment of the variant albumin with which it is compared. Similarlythe corresponding fusion polypeptide comprising HSA or conjugatecomprising HSA is intended to mean molecules having same size and aminoacid sequence as the fusion polypeptide of conjugate comprising variantalbumin, with which it is compared.

The composition may comprise a pharmaceutically acceptable carrier orexcipient such as water, polysorbate 80 or those specified in the USPharmacopoeia for human albumin.

Further preferences for the ninth aspect of the invention include thoseof the first aspect of the invention and those provided below thetwelfth aspect of the invention. The skilled person understands that anyaspect of the invention may be combined with another aspect or aspectsof the invention and/or with one or more (several) of the preferencesfor the aspects of the invention and/or other disclosures made herein.

Nanoparticles

A tenth aspect of the invention relates to a nanoparticle comprising avariant, fusion, conjugate, associate, nanoparticle, composition orpolynucleotide as disclosed herein.

Techniques for incorporation of a molecule into nano- or microparticlesare known in the art. Preferred methods for preparing nano- ormicroparticles that may be applied to the albumin, variant, fragment,fusion, conjugate or associate thereof according to the invention isdisclosed in WO 2004/071536 or WO2008/007146 or Oner & Groves(Pharmaceutical Research, Vol 10(9), 1993, pages 1387 to 1388) which areincorporated herein by reference. Preferably the average diameter of anano-particle is from 5 to 1000 nm, more preferably 5, 10, 20, 30, 40,50, 80, 100, 130, 150, 200, 300, 400, 500, 600, 700, 800, 900, or 999 to5, 10, 20, 30, 40, 50, 80, 100, 130, 150, 200, 300, 400, 500, 600, 700,800, 900, or 1000 nm. An advantage of a microparticle less than 200 nmdiameter, and more particularly less than 130 nm, is that is amenable tosterilization by filtration through a 0.2 μm (micron) filter.Preferably, the average diameter of a micro-particle is from 1000 nm (1μm (micron)) to 100 μm (micron), more preferably from 1, 2, 5, 10, 20,30, 40, 50, 60, 70, 80, 90, 100 to 1, 2, 5, 10, 20, 30, 40, 50, 60, 70,80, 90, 100 μm (micron).

Further preferences for the tenth aspect of the invention include thoseof the first aspect of the invention and those provided below thetwelfth aspect of the invention. The skilled person understands that anyaspect of the invention may be combined with another aspect or aspectsof the invention and/or with one or more (several) of the preferencesfor the aspects of the invention and/or other disclosures made herein.

Uses

An eleventh aspect of the invention relates to use of a variant albumin,fragment, fusion or conjugate thereof or nanoparticle or associatethereof. Use may be, for example, in a method of treatment, prophylaxis,diagnosis or imaging. The variant albumin or fragments thereof or fusionpolypeptides comprising variant albumin or fragments thereof accordingto the invention have the benefit that their binding affinity to FcRnand/or plasma half-life is altered compared to the parent or referencealbumin or fragments thereof or fusion polypeptides comprising parent orreference albumin or fragments thereof. This has the advantage that thebinding affinity to FcRn and/or plasma half-life of conjugatescomprising variant albumin or a fragment thereof or fusion polypeptidecomprising variant albumin or a fragment thereof, or an associatecomprising variant albumin or a fragment thereof according to theinvention can be selected in accordance with the particular therapeuticpurpose.

In some situations, it would be advantageous to use an albumin, variant,fragment, fusion, conjugate or associate or composition thereof having alonger plasma half-life than the reference molecule or composition sincethis would have the benefit that the administration of the albumin,variant, fragment, fusion, conjugate or associate or composition thereofwould be needed less frequently or at a reduced dose (and consequentlywith fewer side effects) compared to the situation where the referencemolecule or composition was used. With respect to the use of a variant,fusion, conjugate, associate, nanoparticle, composition orpolynucleotide the albumin moiety may comprise one more alterations asdisclosed herein.

In other situations, it would be advantageous to use an albumin,variant, fragment, fusion, conjugate or associate or composition thereofhaving a shorter plasma half-life than the reference molecule orcomposition since this would have the benefit that the administration ofthe albumin, variant, fragment, fusion, conjugate or associate orcomposition thereof can be carried out at a higher dose compared to thesituation where the reference molecule or composition was used with thebenefit that the administered compound clears from the recipient morequickly than if the reference molecule or composition was used. Withrespect to the use of a variant, fusion, conjugate, associate,nanoparticle, composition or polynucleotide the albumin moiety maycomprise one more alterations as disclosed herein.

For example for a conjugate, associate or fusion polypeptide used forimaging purposes in animals or human beings, where the imaging moietyhas an very short half-life and a conjugate or a fusion polypeptidecomprising HSA has a plasma half-life that is far longer than needed forthe imaging purposes it would be advantageous to use a variant albuminor fragment thereof of the invention having a shorter plasma half-lifethan the parent or reference albumin or fragment thereof, to provideconjugates of fusion polypeptides having a plasma half-life that issufficiently long for the imaging purpose but sufficiently short to becleared form the body of the particular patient on which it is applied.

In another example for a conjugate, an associate or fusion polypeptidecomprising a therapeutic compound effective to treat or alleviate aparticular condition in a patient in need for such a treatment it wouldbe advantageous to use the variant albumin or fragment thereof having alonger plasma half-life than the parent or reference albumin or fragmentthereof, to provide associates or conjugates or fusion polypeptideshaving longer plasma half-lives which would have the benefit that theadministration of the associate or conjugate or fusion polypeptide ofthe invention would be needed less frequently or reduced dose with lessside effects compared to the situation where the parent or referencealbumin or associates thereof or fragment thereof was used. For example,the invention provides a method of treating a proliferative disease inan individual, comprising administering the individual an effectiveamount of an associate according to the invention in which the associatecomprises a taxane, a taxol or taxol derivative (e.g. paclitaxel).

In a further aspect the invention relates to compositions comprising thevariant albumin, associates thereof or fragment thereof, variant albuminfragment or associates thereof or fusion polypeptide comprising variantalbumin or fragment thereof according to the invention. The compositionsare preferably pharmaceutical compositions. The composition may beprepared using techniques known in the area such as disclosed inrecognized handbooks within the pharmaceutical field. Since the albumin,variant, fragment, fusion, conjugate or associate thereof has a bindingaffinity to FcRn and/or plasma half-life which is modulated (i.e.stronger or weaker and/or longer or shorter) than that of a referencemolecule, the composition also has a binding affinity to FcRn and/ormodulated (i.e. altered) plasma half-life relative to an equivalentcomposition comprising the reference molecule in place of the albumin,variant, fragment, fusion, conjugate or associate thereof as describedherein. The composition may be a vaccine. The polypeptide according tothe invention may be an active pharmaceutical or an excipient.Optionally, the composition is provided in unit dosage form.

Preferably the albumin, variant, fragment, fusion, conjugate orassociate thereof has a plasma half-life that is longer than the plasmahalf-life of the reference molecule e.g. the same composition exceptthat the albumin component (e.g. albumin, variant, fragment, fusion,conjugate or associate) is wild-type albumin (e.g. HSA) or a variant,fragment, fusion, conjugate or associate.

In a particular embodiment the compositions comprise a variant albuminor a fragment thereof according to the invention and a compoundcomprising a pharmaceutically beneficial moiety and an albumin bindingdomain (ABD). According to the invention ABD means a site, moiety ordomain capable of binding to circulating albumin in vivo and therebyconferring transport in the circulation of the ABD and any compound ormoiety bound to said ABD. ABD's are known in the art and have been shownto bind very tight to albumin so a compound comprising an ABD bound toalbumin will to a certain extent behave as a single molecule. Theinventors have realized by using the variant albumin or fragment thereofaccording to the invention together with a compound comprising apharmaceutically beneficial moiety and an ABD makes it possible to alterthe binding affinity to FcRn and/or plasma half-life of the compoundcomprising a pharmaceutically beneficial moiety and an ABD compared tothe situation where said compound were injected as such in a patienthaving need thereof or administered in a formulation comprising naturalalbumin or a fragment thereof.

The variant albumin or fragments thereof, conjugates comprising variantalbumin or a fragment thereof or fusion polypeptide comprising variantalbumin or a fragment thereof, or an associate comprising variantalbumin or a fragment thereof according to the invention may also beincorporated into nano- or microparticles using techniques well knownwithin the art. A preferred method for preparing nano- or microparticlesthat may be applied to the variant albumins or fragments thereofaccording to the invention is disclosed in WO 2004/071536 orWO2008/007146 or Oner & Groves (Pharmaceutical Research, Vol 10(9),1993, pages 1387 to 1388) which are incorporated herein by reference.

Further preferences for the eleventh aspect of the invention includethose of the first aspect of the invention and those provided below thetwelfth aspect of the invention. The skilled person understands that anyaspect of the invention may be combined with another aspect or aspectsof the invention and/or with one or more (several) of the preferencesfor the aspects of the invention and/or other disclosures made herein.

Method for Altering the FcRn-Binding Affinity or Half-Life of a Molecule

A twelfth aspect of the invention provides a method for altering theFcRn-binding affinity or half-life of a molecule comprising:

(a) where the molecule is a polypeptide, fusing or conjugating themolecule to a polypeptide disclosed herein or to a conjugate disclosedherein; associating the molecule to a polypeptide disclosed herein or toa conjugate disclosed herein; incorporating the molecule in ananoparticle disclosed herein or a composition disclosed herein;

(b) where the molecule is not a polypeptide, conjugating the molecule toa polypeptide disclosed herein or to a conjugate disclosed herein;associating the molecule to a polypeptide disclosed herein or to aconjugate a disclosed herein; incorporating the molecule in ananoparticle disclosed herein or a composition disclosed herein.

Examples of ‘molecule’ include those useful in therapy, prophylaxis(including those used in vaccines either as an active pharmaceuticalingredient or as an excipient), imaging and diagnosis, such as thosedescribed herein.

Further preferences for the twelfth aspect of the invention includethose of the first aspect of the invention and those provided below thistwelfth aspect of the invention. The skilled person understands that anyaspect of the invention may be combined with another aspect or aspectsof the invention and/or with one or more (several) of the preferencesfor the aspects of the invention and/or other disclosures made herein.

Preferences for all aspects of the invention are provided below. Theskilled person understands that any aspect of the invention may becombined with another aspect or aspects of the invention and/or with oneor more (several) of the preferences for the aspects of the inventionand/or other disclosures made herein.

The variant of albumin or a fragment thereof or fusion polypeptidescomprising variant albumin or fragments thereof, fragment thereof,conjugate, nanoparticle, associate or composition may have a plasmahalf-life that is either longer or shorter, preferably longer, than theplasma half-life than a corresponding albumin or a fragment thereof orfusion polypeptides comprising albumin or fragments thereof, fragmentthereof, conjugate, nanoparticle, associate or composition or a bindingto FcRn that is stronger or weaker, preferably weaker. Preferably thevariant of albumin or a fragment thereof or fusion polypeptidescomprising variant albumin or fragments thereof, fragment thereof,conjugate, nanoparticle, associate or composition has a plasma half-lifethat is longer than the plasma half-life of HSA or the correspondingalbumin or a fragment thereof or fusion polypeptides comprising albuminor fragments thereof, fragment thereof, conjugate, nanoparticle,associate or composition.

Alternatively, this may be expressed as the variant of albumin or afragment thereof or fusion polypeptides comprising variant albumin orfragments thereof, fragment thereof, conjugate, nanoparticle, associateor composition having a KD to FcRn (e.g. shFcRn) that is lower than thecorresponding KD for HSA to FcRn or the corresponding fragment thereofor fusion polypeptide comprising HSA or fragment thereof. Preferably,the KD for the variant of albumin or a fragment thereof or fusionpolypeptides comprising variant albumin or fragments thereof, fragmentthereof, conjugate, nanoparticle, associate or composition is less than0.9×KD for HSA to FcRn, more preferred less than 0.5×KD for HSA to FcRn,more preferred less than 0.1×KD for HSA to FcRn, even more preferredless than 0.05×KD for HSA to FcRn, even more preferred less than 0.02×KDfor HSA to FcRn and most preferred less than 0.01×KD for HSA to FcRn(where X means ‘multiplied by’). The KD of the variant of albumin or afragment thereof or fusion polypeptides comprising variant albumin orfragments thereof, fragment thereof, conjugate, nanoparticle, associateor composition may be between the KD of WT albumin (e.g. SEQ ID No. 2)for FcRn and the KD of HSA K573P (SEQ ID No. 3) for FcRn. Such KDsrepresent binding affinities that are higher than the binding affinitybetween HSA and FcRn. A higher binding affinity indicates a longerhalf-life, for example plasma half-life.

Alternatively, the variant of albumin or a fragment thereof or fusionpolypeptides comprising variant albumin or fragments thereof, fragmentthereof, conjugate, nanoparticle, associate or composition has a plasmahalf-life that is shorter than the plasma half-life of HSA or thecorresponding fragment thereof or fusion polypeptide comprising HSA orfragment thereof.

This may be expressed as the variant of albumin or a fragment thereof orfusion polypeptides comprising variant albumin or fragments thereof,fragment thereof, conjugate, nanoparticle, associate or compositionhaving a KD to FcRn that is higher than the corresponding KD for HSA toFcRn or the corresponding of albumin or a fragment thereof or fusionpolypeptides comprising albumin or fragments thereof, fragment thereof,conjugate, nanoparticle, associate or composition. Preferably, the KDfor the variant of albumin or a fragment thereof or fusion polypeptidescomprising variant albumin or fragments thereof, fragment thereof, or aconjugate comprising a variant of albumin or a fragment thereof is morethan 2×KD for HSA to FcRn, more preferred more than 5×KD for HSA toFcRn, more preferred more than 10×KD for HSA to FcRn, even morepreferred more than 25×KD for HSA to FcRn, even most preferred more than50×KD for HSA to FcRn. The variant of albumin or a fragment thereof orfusion polypeptides comprising variant albumin or fragments thereof,fragment thereof, conjugate, nanoparticle, associate or composition maybe a null binder to FcRn.

The variant of albumin or a fragment thereof or fusion polypeptidescomprising variant albumin or fragments thereof, fragment thereof, or aconjugate or nanoparticle or associate or composition comprising avariant of albumin or a fragment thereof is preferably the variant ofalbumin or a fragment thereof or fusion polypeptides comprising variantalbumin or fragments thereof, fragment thereof, or a conjugate ornanoparticle or associate or composition comprising a variant of albuminor a fragment thereof according to the invention. A lower bindingaffinity indicates a shorter half-life, for example plasma half-life.

One advantage of the invention is that it allows the half-life ofalbumin, a variant of albumin or a fragment thereof or fusionpolypeptides comprising variant albumin or fragments thereof, fragmentthereof, conjugate, nanoparticle, associate or composition to betailored in order to achieve a binding affinity or half-life which meetsthe needs of the user.

When determining and/or comparing KD, one or more (and preferably all)of the following parameters may be used:

Instrument: Biacore 3000 instrument (GE Healthcare)

Flow cell: CM5 sensor chip

FcRn: human FcRn, preferably soluble human FcRn, optionally coupled to atag such as GST or His, most preferably His such as 6 histidines at theC-terminus of the beta-2-microglobulin (SEQ ID NO: 31).

Quantity of FcRn: 1200-2500 RU

Coupling chemistry: amine coupling chemistry (e.g. as described in theprotocol provided by the manufacturer of the instrument).

Coupling method: The coupling may be performed by injecting 20 μg/ml ofthe protein in 10 mM sodium acetate pH 5.0 (GE Healthcare). Phosphatebuffer (67 mM phosphate buffer, 0.15 M NaCl, 0.005% Tween 20) at pH 5.5)may be used as running buffer and dilution buffer. Regeneration of thesurfaces may be done using injections of HBS-EP buffer (0.01 M HEPES,0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20) at pH 7.4 (Biacore AB).

Quantity of injection of test molecule (e.g. HSA or variant) 20-0.032 μM

Flow rate of injection: constant, e.g. 30 μl/ml

Temperature of injection: 25° C.

Data evaluation software: BIAevaluation 4.1 software (BIAcore AB).

The preferred method for determining KD is provided in Example 2.

The invention discloses that one or more (several) positions in Domain Iin combination with one or more (several) positions in Domain III in SEQID NO: 2 (and therefore equivalent positions in albumins and fragmentsfrom human serum and albumin and non-human serum albumins) may bealtered in order to modulate (increase of decrease) the binding affinityand/or half-life e.g. plasma half-life of an albumin, fragment, fusion,conjugate, associate, nanoparticle or composition. An alteration may bea substitution, insertion or deletion. Substitution is preferred.

A substitution or insertion may or may not comprise introduction of aconserved amino acid, i.e. conserved in relation to the amino acid atthe position of interest. Examples of conserved amino acids are shown bythe groups of FIG. 3: aliphatic, aromatic, hydrophobic, charged, polar,positive, tiny and small.

At position 82 of SEQ ID NO: 2 (or equivalent position of other albuminsor variants of fragments thereof), it is preferred that the alterationis a substitution, such as from the native amino acid to A, C, D, E, F,G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, more preferred to Q, D, A,even more preferred to D, A and most preferred to A. In SEQ ID NO: 2 thenative amino acid at position 82 is glutamic acid, therefore asubstitution to glutamic acid is not preferred.

At position 83 of SEQ ID NO: 2 (or equivalent position of other albuminsor variants of fragments thereof), it is preferred that the alterationis a substitution, such as from the native amino acid to A, C, D, E, F,G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, more preferred to N, K, S,even more preferred to N, K and most preferred to N. In SEQ ID NO: 2 thenative amino acid at position 83 is threonine, therefore a substitutionto threonine is not preferred.

At position 111 of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof), it is preferred that thealteration is a substitution, such as from the native amino acid to A,C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, more preferredto N, E, Q, D, G, H, even more preferred to E, Q and most preferred toE. In SEQ ID NO: 2 the native amino acid at position 111 is asparagine,therefore a substitution to asparagine is not preferred.

At position 112 of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof), it is preferred that thealteration is a substitution, such as from the native amino acid to A,C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, more preferredto F, Y, W, even more preferred to F, Y and most preferred to F. In SEQID NO: 2 the native amino acid at position 112 is leucine, therefore asubstitution to leucine is not preferred.

At position 573 of SEQ ID NO: 2 (or equivalent position of otheralbumins or variants of fragments thereof), it is preferred that thealteration is a substitution, such as from the native amino acid to A,C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, more preferredto P, Y, W, H, F, T, I or V, even more preferred to P, Y or W and mostpreferred to P. In SEQ ID NO: 2 the native amino acid at position 573 islysine, therefore a substitution to lysine is not preferred.

It is preferred that the alteration at position 82 is conserved relativeto A. It is preferred that the alteration at position 83 is conservedrelative to N. It is preferred that the alteration at position 111 isconserved relative to E. It is preferred that the alteration at position112 is conserved relative to F. It is preferred that the alteration atposition 573 is conserved relative to P.

Particularly preferred albumin variants comprise substitutionsT83N/N111E (e.g. SEQ ID NO: 32); T83N/N111E/K573P (e.g. SEQ ID NO: 33);T83N/K573P (e.g. SEQ ID NO: 34); T83K/K573P (e.g. SEQ ID NO: 38);E82A/K573P (e.g. SEQ ID NO: 39); L112F/K573P (e.g. SEQ ID NO: 40);E82D/K573P (e.g. SEQ ID NO: 43); P110G/K573P (e.g. SEQ ID NO: 44);N111D/K573P (e.g. SEQ ID NO: 60); N111G/K573P (e.g. SEQ ID NO: 61);N111H/K573P (e.g. SEQ ID NO: 62); E425A/K573P (e.g. SEQ ID NO: 64);E505Q/K573P (e.g. SEQ ID NO: 65); T527M/K573P (e.g. SEQ ID NO: 66);N111E/K573P (e.g. SEQ ID NO: 68); K534V/K573P (e.g. SEQ ID NO: 73);N111Q/K573P (e.g. SEQ ID NO: 74) which are descried with reference toHSA (SEQ ID NO: 2). Other preferred albumin variants comprise equivalentsubstitutions in albumins other than HSA (SEQ ID NO: 2).

Also, an albumin variant according to the invention may comprise one ormore (several) alterations at positions selected from 78 to 88 and/or105 to 120 and/or 425, 505, 510, 512, 524, 527, 531, 534, 569, 575 ofHSA (SEQ ID NO: 2) or equivalent positions of other albumins. Preferredalterations are substitutions such as those described for thesepositions in the first aspect of the invention. Particularly preferredsubstitutions include D108A (SEQ ID NO: 59); D108E (e.g. SEQ ID NO: 70);N109K (e.g. SEQ ID NO: 69); P110G (e.g. SEQ ID NO: 42); N111D (e.g. SEQID NO: 46); N111E (e.g. SEQ ID NO: 67); N111G (e.g. SEQ ID NO: 48);N111H (e.g. SEQ ID NO: 49); N111K (e.g. SEQ ID NO: 54); L112F (e.g. SEQID NO: 37); E425A (e.g. SEQ ID NO: 63); E425K (e.g. SEQ ID NO: 55);E505Q (e.g. SEQ ID NO: 45); H510D (e.g. SEQ ID NO: 57); D512E (e.g. SEQID NO: 50); K524A (e.g. SEQ ID NO: 51); T527A (e.g. SEQ ID NO: 52);T527M (e.g. SEQ ID NO: 47); E531H (e.g. SEQ ID NO: 53); K534V (e.g. SEQID NO: 56); A569S (e.g. SEQ ID NO: 58); L575F (e.g. SEQ ID NO: 72); E82A(e.g. SEQ ID NO: 36); E82D (e.g. SEQ ID NO: 41); T83K (e.g. SEQ ID NO:35); T83N (e.g. SEQ ID NO: 71) which are descried with reference to HSA(SEQ ID NO: 2). Other preferred albumin variants comprising one or more(several) alterations may comprise equivalent substitutions in albuminsother than HSA (SEQ ID NO: 2).

Advantageously, the polypeptide retains substantially the same tertiarystructure (or, for a fragment, the relevant part of the structure) as areference or parent albumin such as HSA. The skilled person understandthe term ‘substantially the same tertiary structure’ bearing in mindthat some degree of variation in tertiary structure is expected as allproteins have some degree of structural flexibility. This appliesparticularly to polypeptides having a higher binding affinity to FcRnthan the parent or reference albumin (e.g. HSA) has to FcRn.

One or more (several) of the His residues may or may not be maintainedrelative to the parent albumin. For example, with reference to SEQ IDNO: 2, one or more (several) of the following His residues may bemaintained: 3, 9, 39, 67, 105, 128, 146, 242, 247, 288, 338, 367, 440,464, 510, and/or 535. One or more (several), preferably all, of the Hisresidues in domain I are maintained (i.e. 3, 9, 39, 67, 105, 128, 146.).One or more (several), preferably all, of the His residues in domain IIare maintained (i.e. 242, 247, 288, 338, 367). One or more (several),preferably all, of the His residues in domain III are maintained (i.e.440, 464, 510, 535). One or more (several) or all three of His 464, 510,535 may be maintained.

It is preferred that at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16 or 17 of the disulphide bonds of the albumin are maintainedin the polypeptide. For a polypeptide derived from a full lengthalbumin, it is preferred that all disulphide bonds usually present inthat albumin are maintained. For a polypeptide derived from a fragmentof albumin, it is preferred that all disulphide bonds usually present inthat fragment are maintained. It is preferred that Cys34 (or equivalentin non-human albumins) is maintained.

For all aspects of the invention fusion partner polypeptides and/orconjugates may comprise one or more (several) of: 4-1BB ligand, 5-helix,A human C-C chemokine, A human L105 chemokine, A human L105 chemokinedesignated huL105_(—)3., A monokine induced by gamma-interferon (MIG), Apartial CXCR4B protein, A platelet basic protein (PBP), α1-antitrypsin,ACRP-30 Homologue; Complement Component C1q C, Adenoid-expressedchemokine (ADEC), aFGF; FGF-1, AGF, AGF Protein, albumin, an etoposide,angiostatin, Anthrax vaccine, Antibodies specific for collapsin,antistasin, Anti-TGF beta family antibodies, antithrombin III, APM-1;ACRP-30; Famoxin, apo-lipoprotein species, Arylsulfatase B, b57 Protein,BCMA, Beta-thromboglobulin protein (beta-TG), bFGF; FGF2, Bloodcoagulation factors, BMP Processing Enzyme Furin, BMP-10, BMP-12,BMP-15, BMP-17, BMP-18, BMP-2B, BMP-4, BMP-5, BMP-6, BMP-9, BoneMorphogenic Protein-2, calcitonin, Calpain-10a, Calpain-10b,Calpain-10c, Cancer Vaccine, Carboxypeptidase, C-C chemokine, MCP2, CCR5variant, CCR7, CCR7, CD11a Mab, CD137; 4-1BB Receptor Protein, CD20 Mab,CD27, CD27L, CD30, CD30 ligand, CD33 immunotoxin, CD40, CD40L, CD52 Mab,Cerebus Protein, Chemokine Eotaxin, Chemokine hIL-8, Chemokine hMCP1,Chemokine hMCP1a, Chemokine hMCP1b, Chemokine hMCP2, Chemokine hMCP3,Chemokine hSDF1b, Chemokine MCP-4, chemokine TECK and TECK variant,Chemokine-like protein IL-8M1 Full-Length and Mature, Chemokine-likeprotein IL-8M10 Full-Length and Mature, Chemokine-like protein IL-8M3,Chemokine-like protein IL-8M8 Full-Length and Mature, Chemokine-likeprotein IL-8M9 Full-Length and Mature, Chemokine-like protein PF4-414Full-Length and Mature, Chemokine-like protein PF4-426 Full-Length andMature, Chemokine-like protein PF4-M2 Full-Length and Mature, Choleravaccine, Chondromodulin-like protein, c-kit ligand; SCF; Mast cellgrowth factor; MGF; Fibrosarcoma-derived stem cell factor, CNTF andfragment thereof (such as CNTFAx15′ (Axokine™)), coagulation factors inboth pre and active forms, collagens, Complement C5 Mab, Connectivetissue activating protein-III, CTAA16.88 Mab, CTAP-III, CTLA4-Ig,CTLA-8, CXC3, CXC3, CXCR3; CXC chemokine receptor 3, cyanovirin-N,Darbepoetin, designated exodus, designated huL105_(—)7, DIL-40, DNase,EDAR, EGF Receptor Mab, ENA-78, Endostatin, Eotaxin, Epithelialneutrophil activating protein-78, EPO receptor; EPOR, erythropoietin(EPO) and EPO mimics, Eutropin, Exodus protein, Factor IX, Factor VII,Factor VIII, Factor X and Factor XIII, FAS Ligand Inhibitory Protein(DcR3), FasL, FasL, FasL, FGF, FGF-12; Fibroblast growth factorhomologous factor-1, FGF-15, FGF-16, FGF-18, FGF-3; INT-2, FGF-4;gelonin, HST-1; HBGF-4, FGF-5, FGF-6; Heparin binding secretedtransforming factor-2, FGF-8, FGF-9; Glia activating factor, fibrinogen,flt-1, flt-3 ligand, Follicle stimulating hormone Alpha subunit,Follicle stimulating hormone Beta subunit, Follitropin, Fractalkine,fragment. myofibrillar protein Troponin I, FSH, Galactosidase,Galectin-4, G-CSF, GDF-1, Gene therapy, Glioma-derived growth factor,glucagon, glucagon-like peptides, Glucocerebrosidase, glucose oxidase,Glucosidase, Glycodelin-A; Progesterone-associated endometrial protein,GM-CSF, gonadotropin, Granulocyte chemotactic protein-2 (GCP-2),Granulocyte-macrophage colony stimulating factor, growth hormone, Growthrelated oncogene-alpha (GRO-alpha), Growth related oncogene-beta(GRO-beta), Growth related oncogene-gamma (GRO-gamma), hAPO-4; TROY,hCG, Hepatitis B surface Antigen, Hepatitis B Vaccine, HER2 ReceptorMab, hirudin, HIV gp120, HIV gp41, HIV Inhibitor Peptide, HIV InhibitorPeptide, HIV Inhibitor Peptide, HIV protease inhibiting peptides, HIV-1protease inhibitors, HPV vaccine, Human 6CKine protein, Human Act-2protein, Human adipogenesis inhibitory factor, human B cell stimulatingfactor-2 receptor, Human beta-chemokine H1305 (MCP-2), Human C-Cchemokine DGWCC, Human CC chemokine ELC protein, Human CC type chemokineinterleukin C, Human CCC3 protein, Human CCF18 chemokine, Human CC-typechemokine protein designated SLC (secondary lymphoid chemokine), Humanchemokine beta-8 short forms, Human chemokine 010, Human chemokine CC-2,Human chemokine CC-3, Human chemokine CCR-2, Human chemokine Ckbeta-7,Human chemokine ENA-78, Human chemokine eotaxin, Human chemokine GROalpha, Human chemokine GROalpha, Human chemokine GRObeta, Humanchemokine HCC-1, Human chemokine HCC-1, Human chemokine 1-309, Humanchemokine IP-10, Human chemokine L105_(—)3, Human chemokine L105_(—)7,Human chemokine MIG, Human chemokine MIG-beta protein, Human chemokineMIP-1alpha, Human chemokine MIP1beta, Human chemokine MIP-3alpha, Humanchemokine MIP-3beta, Human chemokine PF4, Human chemokine protein 331D5,Human chemokine protein 61164, Human chemokine receptor CXCR3, Humanchemokine SDF1alpha, Human chemokine SDF1beta, Human chemokine ZSIG-35,Human Chr19Kine protein, Human CKbeta-9, Human CKbeta-9, Human CX3C 111amino acid chemokine, Human DNAX interleukin-40, Human DVic-1 C-Cchemokine, Human EDIRF 1 protein sequence, Human EDIRF II proteinsequence, Human eosinocyte CC type chemokine eotaxin, Humaneosinophil-expressed chemokine (EEC), Human fast twitch skeletal muscletroponin C, Human fast twitch skeletal muscle troponin 1, Human fasttwitch skeletal muscle Troponin subunit C, Human fast twitch skeletalmuscle Troponin subunit 1 Protein, Human fast twitch skeletal muscleTroponin subunit T, Human fast twitch skeletal muscle troponin T, Humanfoetal spleen expressed chemokine, FSEC, Human GM-CSF receptor, Humangro-alpha chemokine, Human gro-beta chemokine, Human gro-gammachemokine, Human IL-16 protein, Human IL-1RD10 protein sequence, HumanIL-1RD9, Human IL-5 receptor alpha chain, Human IL-6 receptor, HumanIL-8 receptor protein hIL8RA, Human IL-8 receptor protein hIL8RB, HumanIL-9 receptor protein, Human IL-9 receptor protein variant #3, HumanIL-9 receptor protein variant fragment, Human IL-9 receptor proteinvariant fragment #3, Human interleukin 1 delta, Human Interleukin 10,Human Interleukin 10, Human interleukin 18, Human interleukin 18derivatives, Human interleukin-1 beta precursor, Human interleukin-1beta precursor, Human interleukin-1 receptor accessory protein, Humaninterleukin-1 receptor antagonist beta, Human interleukin-1 type-3receptor, Human Interleukin-10 (precursor), Human Interleukin-10(precursor), Human interleukin-11 receptor, Human interleukin-12 40 kDsubunit, Human interleukin-12 beta-1 receptor, Human interleukin-12beta-2 receptor, Human Interleukin-12 p35 protein, Human Interleukin-12p40 protein, Human interleukin-12 receptor, Human interleukin-13 alphareceptor, Human interleukin-13 beta receptor, Human interleukin-15,Human interleukin-15 receptor from clone P1, Human interleukin-17receptor, Human interleukin-18 protein (IL-18), Human interleukin-3,human interleukin-3 receptor, Human interleukin-3 variant, Humaninterleukin-4 receptor, Human interleukin-5, Human interleukin-6, Humaninterleukin-7, Human interleukin-7, Human interleukin-8 (IL-8), Humanintracellular IL-1 receptor antagonist, Human IP-10 and HIV-1 gp120hypervariable region fusion protein, Human IP-10 and human Muc-1 coreepitope (VNT) fusion protein, human liver and activation regulatedchemokine (LARC), Human Lkn-1 Full-Length and Mature protein, Humanmammary associated chemokine (MACK) protein Full-Length and Mature,Human mature chemokine Ckbeta-7, Human mature gro-alpha, Human maturegro-gamma polypeptide used to treat sepsis, Human MCP-3 and human Muc-1core epitope (VNT) fusion protein, Human MI10 protein, Human MI1Aprotein, Human monocyte chemoattractant factor hMCP-1, Human monocytechemoattractant factor hMCP-3, Human monocyte chemotactic proprotein(MCPP) sequence, Human neurotactin chemokine like domain, Human non-ELRCXC chemokine H174, Human non-ELR CXC chemokine IP10, Human non-ELR CXCchemokine Mig, Human PAI-1 mutants, Human protein with IL-16 activity,Human protein with IL-16 activity, Human secondary lymphoid chemokine(SLC), Human SISD protein, Human STCP-1, Human stromal cell-derivedchemokine, SDF-1, Human T cell mixed lymphocyte reaction expressedchemokine (TMEC), Human thymus and activation regulated cytokine (TARC),Human thymus expressed, Human TNF-alpha, Human TNF-alpha, Human TNF-beta(LT-alpha), Human type CC chemokine eotaxin 3 protein sequence, Humantype II interleukin-1 receptor, Human wild-type interleukin-4 (hIL-4)protein, Human ZCHEMO-8 protein, Humanized Anti-VEGF Antibodies, andfragments thereof, Humanized Anti-VEGF Antibodies, and fragmentsthereof, Hyaluronidase, ICE 10 kD subunit, ICE 20 kD subunit, ICE 22 kDsubunit, Iduronate-2-sulfatase, Iduronidase, IL-1 alpha, IL-1 beta, IL-1inhibitor (IL-1i), IL-1 mature, IL-10 receptor, IL-11, IL-11, IL-12 p40subunit, IL-13, IL-14, IL-15, IL-15 receptor, IL-17, IL-17 receptor,Il-17 receptor, Il-17 receptor, IL-19, IL-1i fragments, IL1-receptorantagonist, IL-21 (TIF), IL-3 containing fusion protein, IL-3 mutantproteins, IL-3 variants, IL-3 variants, IL-4, IL-4 mutein, IL-4 muteinY124G, IL-4 mutein Y124X, IL-4 muteins, Il-5 receptor, IL-6, Il-6receptor, IL-7 receptor clone, IL-8 receptor, IL-9 mature proteinvariant (Met117 version), immunoglobulins or immunoglobulin-basedmolecules or fragment of either (e.g. a Small ModularImmunoPharmaceutical™ (“SMIP”) or dAb, Fab′ fragments, F(ab′)2, scAb,scFv or scFv fragment), including but not limited to plasminogen,Influenza Vaccine, Inhibin alpha, Inhibin beta, insulin, insulin-likegrowth factor, Integrin Mab, inter-alpha trypsin inhibitor, inter-alphatrypsin inhibitor, Interferon gamma-inducible protein (IP-10),interferons (such as interferon alpha species and sub-species,interferon beta species and sub-species, interferon gamma species andsub-species), interferons (such as interferon alpha species andsub-species, interferon beta species and sub-species, interferon gammaspecies and sub-species), Interleukin 6, Interleukin 8 (IL-8) receptor,Interleukin 8 receptor B, Interleukin-1alpha, Interleukin-2 receptorassociated protein p43, interleukin-3, interleukin-4 muteins,Interleukin-8 (IL-8) protein, interleukin-9, Interleukin-9 (IL-9) matureprotein (Thr117 version), interleukins (such as M0, IL11 and IL2),interleukins (such as M0, IL11 and IL2), Japanese encephalitis vaccine,Kalikrein Inhibitor, Keratinocyte growth factor, Kunitz domain protein(such as aprotinin, amyloid precursor protein and those described in WO03/066824, with or without albumin fusions), Kunitz domain protein (suchas aprotinin, amyloid precursor protein and those described in WO03/066824, with or without albumin fusions), LACI, lactoferrin, LatentTGF-beta binding protein II, leptin, Liver expressed chemokine-1(LVEC-1), Liver expressed chemokine-2 (LVEC-2), LT-alpha, LT-beta,Luteinization Hormone, Lyme Vaccine, Lymphotactin, Macrophage derivedchemokine analogue MDC (n+1), Macrophage derived chemokine analogueMDC-eyfy, Macrophage derived chemokine analogue MDC-yl, Macrophagederived chemokine, MDC, Macrophage-derived chemokine (MDC), Maspin;Protease Inhibitor 5, MCP-1 receptor, MCP-1a, MCP-1b, MCP-3, MCP-4receptor, M-CSF, Melanoma inhibiting protein, Membrane-bound proteins,Met117 human interleukin 9, MIP-3 alpha, MIP-3 beta, MIP-Gamma, MIRAP,Modified Rantes, monoclonal antibody, MP52, Mutant Interleukin 6 S176R,myofibrillar contractile protein Troponin I, Natriuretic Peptide, NerveGrowth Factor-beta, Nerve Growth Factor-beta2, Neuropilin-1,Neuropilin-2, Neurotactin, Neurotrophin-3, Neurotrophin-4,Neurotrophin-4a, Neurotrophin-4b, Neurotrophin-4c, Neurotrophin-4d,Neutrophil activating peptide-2 (NAP-2), NOGO-66 Receptor, NOGO-A,NOGO-B, NOGO-C, Novel beta-chemokine designated PTEC, N-terminalmodified chemokine GroHEK/hSDF-1alpha, N-terminal modified chemokineGroHEK/hSDF-1beta, N-terminal modified chemokine met-hSDF-1 alpha,N-terminal modified chemokine met-hSDF-1 beta, OPGL, OsteogenicProtein-1; OP-1; BMP-7, Osteogenic Protein-2, OX40; ACT-4, OX40L,Oxytocin (Neurophysin I), parathyroid hormone, Patched, Patched-2,PDGF-D, Pertussis toxoid, Pituitary expressed chemokine (PGEC),Placental Growth Factor, Placental Growth Factor-2, PlasminogenActivator Inhibitor-1; PAI-1, Plasminogen Activator Inhibitor-2; PAI-2,Plasminogen Activator Inhibitor-2; PAI-2, Platelet derived growthfactor, Platelet derived growth factor Bv-sis, Platelet derived growthfactor precursor A, Platelet derived growth factor precursor B, PlateletMab, platelet-derived endothelial cell growth factor (PD-ECGF),Platelet-Derived Growth Factor A chain, Platelet-Derived Growth Factor Bchain, polypeptide used to treat sepsis, Preproapolipoprotein “milano”variant, Preproapolipoprotein “paris” variant, pre-thrombin, Primate CCchemokine “ILINCK”, Primate CXC chemokine “IBICK”, proinsulin,Prolactin, Prolactin2, prosaptide, Protease inhibitor peptides, ProteinC, Protein S, pro-thrombin, prourokinase, RANTES, RANTES 8-68, RANTES9-68, RANTES peptide, RANTES receptor, Recombinant interleukin-16,Resistin, restrictocin, Retroviral protease inhibitors, ricin, RotavirusVaccine, RSV Mab, saporin, sarcin, Secreted and Transmembranepolypeptides, Secreted and Transmembrane polypeptides, serumcholinesterase, serum protein (such as a blood clotting factor), SolubleBMP Receptor Kinase Protein-3, Soluble VEGF Receptor, Stem CellInhibitory Factor, Straphylococcus Vaccine, Stromal Derived Factor-1alpha, Stromal Derived Factor-1 beta, Substance P (tachykinin), T1249peptide, T20 peptide, T4 Endonuclease, TACI, Tarc, TGF-beta 1, TGF-beta2, Thr117 human interleukin 9, thrombin, thrombopoietin, Thrombopoietinderivative1, Thrombopoietin derivative2, Thrombopoietin derivative3,Thrombopoietin derivative4, Thrombopoietin derivative5, Thrombopoietinderivative6, Thrombopoietin derivative7, Thymus expressed chemokine(TECK), Thyroid stimulating Hormone, tick anticoagulant peptide, Tim-1protein, TNF-alpha precursor, TNF-R, TNF-RII; TNF p75 Receptor; DeathReceptor, tPA, transferrin, transforming growth factor beta, Troponinpeptides, Truncated monocyte chemotactic protein 2 (6-76), Truncatedmonocyte chemotactic protein 2 (6-76), Truncated RANTES protein (3-68),tumour necrosis factor, Urate Oxidase, urokinase, Vasopressin(Neurophysin II), VEGF R-3; flt-4, VEGF Receptor; KDR; flk-1, VEGF-110,VEGF-121, VEGF-138, VEGF-145, VEGF-162, VEGF-165, VEGF-182, VEGF-189,VEGF-206, VEGF-D, VEGF-E; VEGF-X, von Willebrand's factor, Wild typemonocyte chemotactic protein 2, Wild type monocyte chemotactic protein2, ZTGF-beta 9, alternative antibody scaffolds e.g. anticalin(s),adnectin(s), fibrinogen fragment(s), nanobodies such as camelidnanobodies, infestin, and/or any of the molecules mentioned inWO01/79271 (particularly page 9 and/or Table 1), WO 2003/59934(particularly Table 1), WO03/060071 (particularly Table 1) orWO01/079480 (particularly Table 1) (each incorporated herein byreference in their entirety).

Furthermore, conjugates may comprise one or more (several) ofchemotherapy drugs such as: 13-cis-Retinoic Acid, 2-CdA,2-Chlorodeoxyadenosine, 5-Azacitidine, 5-Fluorouracil, 5-FU,6-Mercaptopurine, 6-MP, 6-TG, 6-Thioguanine, A, Abraxane, Accutane®,Actinomycin-D, Adriamycin®, Adrucil®, Agrylin®, Ala-Cort®, Aldesleukin,Alemtuzumab, ALIMTA, Alitretinoin, Alkaban-AQ®, Alkeran®,All-transretinoic Acid, Alpha Interferon, Altretamine, Amethopterin,Amifostine, Aminoglutethimide, Anagrelide, Anandron®, Anastrozole,Arabinosylcytosine, Ara-C, Aranesp®, Aredia®, Arimidex®, Aromasin®,Arranon®, Arsenic Trioxide, Asparaginase, ATRA, Avastin®, Azacitidine,BCG, BCNU, Bevacizumab, Bexarotene, BEXXAR®, Bicalutamide, BiCNU,Blenoxane®, Bleomycin, Bortezomib, Busulfan, Busulfex®, C225, CalciumLeucovorin, Campath®, Camptosar®, Camptothecin-11, Capecitabine, Carac™,Carboplatin, Carmustine, Carmustine Wafer, Casodex®, CC-5013, CCNU,CDDP, CeeNU, Cerubidine®, Cetuximab, Chlorambucil, Cisplatin, CitrovorumFactor, Cladribine, Cortisone, Cosmegen®, CPT-11, Cyclophosphamide,Cytadren®, Cytarabine, Cytarabine Liposomal, Cytosar-U®, Cytoxan®,Dacarbazine, Dacogen, Dactinomycin, Darbepoetin Alfa, Dasatinib,Daunomycin, Daunorubicin, Daunorubicin Hydrochloride, DaunorubicinLiposomal, DaunoXome®, Decadron, Decitabine, Delta-Cortef®, Deltasone®,Denileukin diftitox, DepoCyt™, Dexamethasone, Dexamethasone acetate,Dexamethasone Sodium Phosphate, Dexasone, Dexrazoxane, DHAD, DIC,Diodex, Docetaxel, Doxil®, Doxorubicin, Doxorubicin liposomal, Droxia™,DTIC, DTIC-Dome®, Duralone®, Efudex®, Eligard™, Ellence™, Eloxatin™,Elspar®, Emcyt®, Epirubicin, Epoetin alfa, Erbitux™, Erlotinib, ErwiniaL-asparaginase, Estramustine, Ethyol, Etopophos®, Etoposide, EtoposidePhosphate, Eulexin®, Evista®, Exemestane, Fareston®, Faslodex®,Fernara®, Filgrastim, Floxuridine, Fludara®, Fludarabine, Fluoroplex®,Fluorouracil, Fluorouracil (cream), Fluoxymesterone, Flutamide, FolinicAcid, FUDR®, Fulvestrant, G-CSF, Gefitinib, Gemcitabine, Gemtuzumabozogamicin, Gemzar®, Gleevec™, Gliadel® Wafer, GM-CSF, Goserelin,Granulocyte-Colony Stimulating Factor, Granulocyte Macrophage ColonyStimulating Factor, Halotestin®, Herceptin®, Hexadrol, Hexalen®,Hexamethylmelamine, HMM, Hycamtin®, Hydrea®, Hydrocort Acetate®,Hydrocortisone, Hydrocortisone Sodium Phosphate, Hydrocortisone SodiumSuccinate, Hydrocortone Phosphate, Hydroxyurea, Ibritumomab, IbritumomabTiuxetan, Idamycin®, Idarubicin, Ifex®, IFN-alpha, Ifosfamide, IL-11,IL-2, Imatinib mesylate, Imidazole Carboxamide, Interferon alfa,Interferon Alfa-2b (PEG Conjugate), Interleukin-2, Interleukin-11,Intron A® (interferon alfa-2b), Iressa®, Irinotecan, Isotretinoin,Kidrolase®, Lanacort®, Lapatinib, L-asparaginase, LCR, Lenalidomide,Letrozole, Leucovorin, Leukeran, Leukine™, Leuprolide, Leurocristine,Leustatin™, Liposomal Ara-C, Liquid Pred®, Lomustine, L-PAM,L-Sarcolysin, Lupron®, Lupron Depot®, M, Matulane®, Maxidex,Mechlorethamine, Mechlorethamine Hydrochloride, Medralone®, Medrol®,Megace®, Megestrol, Megestrol Acetate, Melphalan, Mercaptopurine, Mesna,Mesnex™, Methotrexate, Methotrexate Sodium, Methylprednisolone,Meticorten®, Mitomycin, Mitomycin-C, Mitoxantrone, M-Prednisol®, MTC,MTX, Mustargen®, Mustine, Mutamycin®, Myleran®, Mylocel™, Mylotarg®,Navelbine®, Nelarabine, Neosar®, Neulasta™, Neumega®, Neupogen®,Nexavar®, Nilandron®, Nilutamide, Nipent®, Nitrogen Mustard, Novaldex®,Novantrone®, Octreotide, Octreotide acetate, Oncospar®, Oncovin®,Ontak®, Onxal™, Oprevelkin, Orapred®, Orasone®, Oxaliplatin, a taxol ortaxol derivative e.g. Paclitaxel or Paclitaxel Protein-bound,Pamidronate, Panitumumab, Panretin®, Paraplatin®, Pediapred®, PEGInterferon, Pegaspargase, Pegfilgrastim, PEG-INTRON™,PEG-L-asparaginase, PEMETREXED, Pentostatin, Phenylalanine Mustard,Platinol®, Platinol-AQ®, Prednisolone, Prednisone, Prelone®,Procarbazine, PROCRIT®, Proleukin®, Prolifeprospan 20 with CarmustineImplant, Purinethol®, R, Raloxifene, Revlimid®, Rheumatrex®, Rituxan®,Rituximab, Roferon-A® (Interferon Alfa-2a), Rubex®, Rubidomycinhydrochloride, Sandostatin®, Sandostatin LAR®, Sargramostim,Solu-Cortef®, Solu-Medrol®, Sorafenib, SPRYCEL™, STI-571, Streptozocin,SU11248, Sunitinib, Sutent®, Tamoxifen, Tarceva®, Targretin®, Taxol®,Taxotere®, Temodar®, Temozolomide, Teniposide, TESPA, Thalidomide,Thalomid®, TheraCys®, Thioguanine, Thioguanine Tabloid®,Thiophosphoamide, Thioplex®, Thiotepa, TICE®, Toposar®, Topotecan,Toremifene, Tositumomab, Trastuzumab, Tretinoin, Trexall™, Trisenox®,TSPA, TYKERB®, VCR, Vectibix™, Velban®, Velcade®, VePesid®, Vesanoid®,Viadur™, Vidaza®, Vinblastine, Vinblastine Sulfate, Vincasar Pfs®,Vincristine, Vinorelbine, Vinorelbine tartrate, VLB, VM-26, Vorinostat,VP-16, Vumon®, Xeloda®, Zanosar®, Zevalin™, Zinecard®, Zoladex®,Zoledronic acid, Zolinza, Zometa®; radiopharmaceuticals such as:Carbon-11, Carbon-14, Chromium-51, Cobalt-57, Cobalt-58, Erbium-169,Fluorine-18, Gallium-67, Gold-198, Indium-111, Indium-113m, Iodine-123,Iodine-125, Iodine-131, Iron-59, Krypton-81m, Nitrogen-13, Oxygen-15,Phosphorous-32, Rhenium-186, Rubidium-82, Samarium-153, Selenium-75,Strontium-89, Technetium-99m, Thallium-201, Tritium, Xenon-127,Xenon-133, Yttrium-90; imaging agents such as Gadolinium, magnetite,manganese, technetium, 1125, 1131, P32, TI201, Iopamidol, PET-FDG.

Further fusion partners, conjugation partners and/or molecules forinclusion in a nanoparticle, associate or composition according to theinvention include: acromegaly drugs e.g. somatuline, lanreotide,octreotide, Sandostatin; antithrombotics e.g. bivalirudin, Angiomax,dalteparin, Fragmin, enoxaparin, Lovenox, Drotrecogin alfa (e.g.Activated), Xigris, heparin; assisted reproductive therapy compoundse.g. choriogonadotropin, Ovidrel, follitropin, alpha/beta; enzymes e.g.hyaluronidase, Hylenex; diabetes drugs e.g. exenatide, Byetta, glucagon,insulin, liraglutide, albiglutide, GLP-1 agonists, exendin or an exendinanalog; compounds useful in diagnosis e.g. protirelin, Thyrel TRHThypinone, secretin (e.g. synthetic human), Chirhostim, thyrotropin(e.g. alpha), Thyrogen' erythropoiesis drugs e.g. Darbepoetin alfa,Aranesp, Epoetin alfa, Epogen, Eprex, drugs for the treatment of geneticdefects e.g. pegademase, drugs for the treatment of growth failure e.g.Adagen, mecasermin, rinfabate, drugs for the treatment of cysticfibrosis e.g. Dornase alfa, Pulmozyme, drugs for the treatment ofmetaoblic disorders e.g. Agalsidase beta, Fabrazyme, alglucosidasealpha, Myozyme, Laronidase, Aldurazyme, drugs for the treatment ofgenital wart intralesional e.g. Interferon alfa-n3, Alferon N, drugs forthe treatment of granulomatous disease e.g. Interferon gamma-1b,Actimmune; drugs for the treatment of growth failure e.g. pegvisomant,Somavert, somatropin, Genotropin, Nutropin, Humatrope, Serostim,Protropin; drugs for the treatment of heart failure e.g. nesiritide,Natrecor; drugs for the treatment of hemophilia e.g. a coagulationfactor e.g. Factor VIII, Helixate FS, Kogenate FS, Factor IX, BeneFIX,Factor Vila, Novoseven, desmopressin, Stimate, DDAVP; hemopoetic drugse.g. Filgrastim (G-CSF), Neupogen, Oprelvekin, Neumega, Pegfilgrastim,Neulasta, Sargramostim, Leukine; drugs for the treatment of hepatitis Ce.g. Interferon alfa-2a, Roferon A, Interferon alfa-2b, Intron A,Interferon alfacon-1, Infergen, Peginterferon alfa-2a, Pegasys,Peginterferon alfa-2b, PEG-Intron; drugs for the treatment of HIV e.g.enfuvirtide, Fuzeon; Fabs e.g. Fab (antithrombin), Abciximab, ReoPro;monoclonal antibodies e.g. Daclizumab, Zenapax; antiviral monoclonalantibodies e.g. Palivizumab, Synagis; monoclonal antibodies for thetreatment of asthma e.g. Omalizumab, Xolair; monoclonal antibodies foruse in diagnostic imaging e.g. Arcitumomab, CEA-Scan, CapromabPendetide, ProstaScint, Satumomab Pendetide, OncoScint CR/OV, Fabs foruse in diagnostic imaging e.g. Nofetumomab, Verluma; immuno-suppressantmonoclonal antibodies e.g. Basiliximab, Simulect, Muromonab-CD3,Orthoclone OKT3; monoclonal antibodies for the treatment of malignancye.g. Alemtuzumab, Campath, Ibritumomab tiuxetan, Zevalin, Rituximab,Rituxan, Trastuzumab, Herceptin; monoclonal antibodies for the treatmentof rheumatoid arthritis (RA) e.g. Adalimumab, Humira, Infliximab,Remicade; monoclonal antibodies for use as a radio-immuno-therapeutice.g. Tositumomab and Iodine I¹³¹, Tositumomab, Bexxar; drugs for thetreatment of macular degeneration e.g. pegaptanib, Macugen; drugs forthe treatment of malignancy e.g. Aldesleukin, Proleukin, Interleukin-2,Asparaginase, Elspar, Rasburicase, Elitek, Denileukin diftitox, Ontak,Pegaspargase, Oncaspar, goserelin, leuprolide; drugs for the treatmentof multiple sclerosis (MS) e.g. Glatiramer acetate (e.g. copolymer-1),Copaxone, Interferon beta-1a, Avonex, Interferon beta-1a, Rebif,Interferon beta-1b, Betaseron; drugs for the treatment of mucositis e.g.palifermin, Kepivance; drug for the treatment of dystonia e.g.,neurotoxin, Botulinum Toxin Type A, BOTOX, BOTOX Cosmetic, BotulinumToxin Type B, MYOBLOC; drugs for the treatment of osteoporosis e.g.teriparatide, Forteo; drugs for the treatment of psoriasis e.g.Alefacept, Amevive; drugs for the treatment of RA e.g. abatacept,Orencia, Anakinra, Kineret, Etanercept, Enbrel; thrombolytics e.g.Alteplase, Activase, recombinant tissue plasminogen activator (rtPA),Anistreplase, Eminase, Reteplase, Retavase, Streptokinase, Streptase,Tenecteplase, TNKase (tenecteplase), Urokinase, Abbokinase, Kinlytic;drugs for the treatment of osteoporosis e.g. calcitonin (e.g. salmon),Miacalcin, Fortical, drugs for the treatment of skin ulcers e.g.Becaplermin, Regranex, Collagenase, Santyl.

Such polypeptides and chemical compounds may be referred to asdiagnostic moieties, therapeutic moieties, prophylactic moieties orbeneficial moieties.

Preferably the fusion partner and/or conjugation partner is not analbumin, variant or fragment thereof.

One or more (several) therapeutic or prophylactic polypeptides may befused to the N-terminus, the C-terminus of albumin, inserted into a loopin the albumin structure or any combination thereof. It may or it maynot comprise linker sequences separating the various components of thefusion polypeptide.

Teachings relating to fusions of albumin or a fragment thereof are knownin the art and the skilled person will appreciate that such teachingscan also be applied to the invention. WO 2001/79271A and WO 2003/59934(incorporated herein by reference) also contain examples of therapeuticand prophylactic polypeptides that may be fused to albumin or fragmentsthereof, and these examples apply also to the invention.

The invention is further described by the following examples that shouldnot be construed as limiting the scope of the invention.

EXAMPLES Example 1 Preparation of HSA Mutein Expression Plasmids

HSA variants were expressed using standard molecular biology techniques,such as described in Sambrook, J. and D. W. Russell, 2001 (MolecularCloning: a laboratory manual, 3^(rd) ed. Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y.).

Construction of the K573P expression plasmid is described inWO2011/051489 (incorporated herein by reference). Construction of theremaining expression plasmids was performed as described in WO2012/150319 (PCT/EP12/058,206, incorporated herein by reference).Variants HSA T83K, HSA E82A, HSA E82D, HSA P110G, HSA L112F and HSAT83N/N111E were produced as described in Example 6, Method 2 of WO2012/150319 (PCT/EP12/058,206, incorporated herein by reference).Combination mutants containing the K573P substitution were produced asdescribed in “Production of combination mutants with K573P” (WO2012/150319 (PCT/EP12/058,206)), where the required fragments wereinserted into appropriately digested pDB4852 (described in WO2012/150319 (PCT/EP12/058,206, incorporated herein by reference)).Fragments containing T83N/N111E, T83K, E82A, E82D, P110G and L112F wereremoved from synthetic constructs via the indicated restriction sites(Table 1). The fragment containing the T83N substitution was removedfrom pDB4874 (described in WO 2012/150319 (PCT/EP12/058,206,incorporated herein by reference)). Ligation of the polynucleotidesencoding HSA variants and plasmids pDB3964/pDB4852 produced plasmids,which were used to express the desired mutants (Table 1). All plasmidswere sequenced to confirm that the HSA sequence was only mutated at thedesired position(s).

Construction of HSA T83N, HSA N111E and HSA N111E/K573P was as describedin WO 2012/150319 (PCT/EP12/058,206, incorporated herein by reference).

Transformation of S. cerevisiae was performed as described in WO2012/150319 (PCT/EP12/058,206, incorporated herein by reference),employing the 24 hour stocking method described in WO 2011/051489, withthe exception that the host strain was S. cerevisiae DYB7 (Payne et al(2008) Applied and Environmental Microbiology Vol. 74(24): 7759-7766)with four copies of PDI integrated into the genome.

TABLE 1 Construction of HSA mutein expression plasmids. Digested SEQRestriction fragment size ID Variant enzymes (kb) Plasmid NO HSAT83N/N111E SacII/NheI 0.395 pDB4966 32 HSA SacII/NheI 0.395 pDB4967 33T83N/N111E/K573P HSA T83N/K573P SacII/NheI 0.395 pDB4968 34 HSA T83KSacII/NheI 0.395 pDB4903 35 HSA E82A SacII/NheI 0.395 pDB4904 36 HSAL112F SacII/NheI 0.395 pDB4907 37 HSA T83K/K573P SacII/NheI 0.395pDB4908 38 HSA E82A/K573P SacII/NheI 0.395 pDB4909 39 HSA L112F/K573PSacII/NheI 0.395 pDB4912 40 HSA E82D SacII/NheI 0.395 pDB4905 41 HSAP110G SacII/NheI 0.395 pDB4906 42 HSA E82D/K573P SacII/NheI 0.395pDB4910 43 HSA P110G/K573P SacII/NheI 0.395 pDB4911 44

Example 2 SPR Analysis of Binding Affinity of Albumin Variants to FcRn

SPR analyses were performed as described in WO 2012/150319(PCT/EP12/058,206, incorporated herein by reference).

The variants were albumin (SEQ ID NO: 2), each with one point mutationselected from: D108A, N111D, N111G, N111H, N111K, K190A, R197A, K276N,R410A, Y411A, P416A, E425A, E425K, K466A, D471A, R472A, N503D, N503K,E505K, E505Q, H510D, H510E, D512A, D512E, K524A, K525A, T527A, T527D,T527M, E531A, E531H, K534V, H535F, E565V, A569L, A569S, A569V, andV576F.

Firstly, the variants were analyzed by SPR to determine their bindingresponse (RU) to shFcRn. Only variants showing a binding response morethan 20% higher or lower than the binding response of wild-type albuminwere analyzed to identify the KD (Table 2, below). Wild-type HSA and HSAwith mutation K573P were used as controls.

TABLE 2 Binding affinity of albumin variants to shFcRn SEQ ID MoleculeNO: Ka (10³/Ms) Kd (10⁻³/s) KD (μM) WT rHSA 2 — — 3.1 ± 0.4* HSA K573P 3— — 0.4 ± 0.1* HSA E505Q 45 2.1 2.9 1.4 HSA N111D 46 0.8 4.4 5.2 HSAT527M 47 2.7 3.3 1.2 HSA N111G 48 1.6 5.2 3.3 HSA N111H 49 0.5 2.4 5.0HSA D512E 50 2.7 10.9 4.1 HSA K524A 51 3.3 11.6 3.5 HSA T527A 52 2.613.7 5.2 HSA E531H 53 3.5 20.8 6.2 HSA N111K 54 0.5 8.3 17.3 HSA E425K55 3.6 12.4 3.5 HSA K534V 56 4.8 5.5 1.1 HSA H510D 57 0.2 0.4 0.2 HSAA569S 58 0.7 4.8 6.8 HSA D108A 59 0.9 12.7 13.7 *Mean of five repeats,therefore Ka and Kd data are not provided

Variants with a lower KD than wild-type HSA have a higher bindingaffinity to shFcRn. Conversely, variants with a higher KD than wild-typeHSA have a lower binding affinity to shFcRn.

The data for positions 108 and 111 support the involvement of a loopincluding positions 105 to 120 in interaction with FcRn and thereforethat alteration at any position within this loop will modulate thebinding affinity of albumin to FcRn.

Example 3 SPR Analysis of Binding Affinity of Albumin Variants to FcRn

The variants were albumin (SEQ ID NO: 2), each with one point mutationselected from: N111D, N111G, N111H, N111D/K573P, N111G/K573P,N111H/K573P, E505Q, E425A, T527M, E505Q/K573P, E425A/K573P andT527M/K573P were prepared as described in above.

TABLE 3 Binding affinity of albumin variants to shFcRn-HIS SEQ IDMolecule NO: Ka (10³/Ms) Kd (10⁻³/s) KD (μM) WT rHSA 2 — — 3.6 ± 0.54* HSA K573P 3 — — 0.6 ± 0.12** HSA N111D 46 9.8 9.1 17.9 17.9 1.8 2.0 HSAN111G 48 7.4 7.4 20.5 19.2 2.7 2.6 HSA N111H 49 4.4 4.0 15.6 14.2 3.53.6 HSA N111D/K573P 60 4.0 4.2 1.9 2.2 0.5 0.5 HSA N111G/K573P 61 4.14.7 1.7 2.3 0.4 0.5 HSA N111H/K573P 62 2.9 3.0 1.7 2.2 0.6 0.7 HSA E505Q45 5.1 5.0 4.9 6.0 1.0 1.2 HSA E425A 63 6.6 7.9 34.1 28.1 5.1 3.6 HSAT527M 47 4.9 4.8 4.4 5.1 0.9 1.1 HSA E425A/K573P 64 3.4 3.6 2.5 3.2 0.70.9 HSA E505Q/K573P 65 0.4 0.4 0.5 1.1 1.6 2.5 HSA T527M/K573P 66 2.62.8 1.2 2.2 0.5 0.8 *Mean of 8 and standard deviation **Mean of 5 andstandard deviation.Variants with a lower KD than wild-type HSA have a higher bindingaffinity to shFcRn. Conversely, variants with a higher KD than wild-typeHSA have a lower binding affinity to shFcRn.

The data for variants including K573P generate increases in affinityconsistent with the K573P substitution only.

Example 4 SPR Analysis of Binding Affinity of Albumin Variants to FcRn

The variants were albumin (SEQ ID NO: 2), each with one point mutationselected from: N111R, N111Q, N111E, N111R/K573P, N111Q/K573P,N111E/K573P, N109D, N109E, N109Q, N109R, N109K, N109H, N109G, D108E,T83N, L575F and K534V/K573P were prepared as described above.

TABLE 4a Binding affinity of albumin variants to shFcRn-HIS SEQ IDMolecule NO: Ka (10³/Ms) Kd (10⁻³/s) KD (μM) WT HSA 2 — — 2.0 ± 0.3* HSA K573P 3 — — 0.3 ± 0.0** HSA N111E 67 15.3 14.3 13.1 15.2 0.8 1.1 HSAN111E/K573P 68 4.2 — 2.4 — 0.6 — HSA N109K 69 9.7 6.3 18.3 21.6 1.9 3.4HSA D108E 70 13.9 7.5 16.6 19.5 1.2 2.6 HSA T83N 71 17.7 15.2 15.6 16.80.9 1.1 HSA L575F 72 11.8 8.3 31.3 32.2 2.7 4.0 HSA K534V/K573P 73 4.74.5 6.9 6.9 1.5 1.5 *Mean of 11 and standard deviation **Mean of 5 andstandard deviation.

TABLE 4b SEQ ID Molecule NO: Ka (10³/Ms) Kd (10⁻³/s) KD (μM) WT rHSA 2 —— 3.6 ± 0.54*  HSA K573P 3 — — 0.6 ± 0.12** HSA N111D 46 9.8 9.1 17.917.9 1.8 2.0 HSA N111G 48 7.4 7.4 20.5 19.2 2.7 2.6 HSA N111H 49 4.4 4.015.6 14.2 3.5 3.6 *Mean of 8 and standard deviation **Mean of 5 andstandard deviation.The data demonstrate a role for the 108 to 111 loop in binding of HSA toFcRn, with reduced binding affinity observed in the D108A and N111Kvariants (Table 2). Additional mutations at position 111 demonstrated arange of binding affinities, from the reduced affinity observed for theN111K variant through to the N111E variant, which displayed an increasedaffinity for FcRn as compared to WT HSA (Table 4). Variant N111Q/K573P(FIG. 5, SEQ ID NO: 74) shows a binding curve with increased responsecompared to wt HSA and slower dissociation compared to wt HSA, this isconsistent with the K573P substitution. The relative position of loopregion 108 to 112 of HSA and FcRn (FIG. 6) suggests that this region haspotential to contribute to FcRn binding as predicted in Example 2.Further details regarding FIGS. 5 and 6 are provided in WO 2012/150319(PCT/EP12/058,206, incorporated herein by reference).

The relative position of adjacent loop region of Domain I (domain 1),comprising residues 78 to 88 (FIG. 6), suggests that this region haspotential to contribute to FcRn binding. This is supported by theobservation that the T83N variant shows increased affinity for FcRncompared to WT HSA (Table 4).

Mutation of the adjacent residues, particularly E82, P110 and L112 (FIG.6), would be predicted to alter the binding affinity of HSA for FcRn.

Example 5 SPR Analysis of Binding Affinity of Albumin Variants to FcRn

SPR analyses were performed on a Biacore 3000 instrument (GEHealthcare). Immobilization was carried out on CM5 chips coupled withshFcRn (GeneArt 1177525) using GE Healthcare amine coupling chemistry asper manufacturer's instructions. Immobilized levels of shFcRn-HIS(shFcRn with a 6-His tail on the C-terminus of beta-2-microglobulin)were ˜1200 RU and achieved by injecting 20 μg/mL shFcRn in sodiumacetate pH4.5 (G E Healthcare). Chip surface was left to stabilize witha constant flow (5 μL/min) of running buffer—Di-basic/Mono-basicphosphate buffer pH5.5 at 25° C. overnight. After ligand stabilization,the chip surface was conditioned by injecting 3×45 μLDi-basic/Mono-basic phosphate buffer at 30 μL/min followed by HBS_EP(0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20) at pH 7.4(GE Healthcare)) regeneration steps (12 s) in between each injection.Surfaces were then checked for activity by injecting 3×45 μL positivecontrol at 30 μL/min, followed by 12 s regeneration pulse.

pH 5.5 Binding Analysis:

Sensorgrams for binding data were obtained by injecting 45 μL of 20 μM(diluted in pH 5.5 buffer) of analytes in pH 5.5 running buffer at 30μL/min in duplicate. 2×12 s regeneration pulses post injection wereperformed to restore the baseline (HBS-EP pH 7.4; 10 μL at 50 μL/min).The reference was then subtracted and BiaEvaluation software 4.1 used toobtain binding analysis data.

pH 5.5 Kinetic Analysis:

Sensorgrams for kinetic data were obtained by injecting 45 μL of fiveconcentrations: 20 μM, 4 μM, 0.8 μM 0.16 μM and 0.032 μM of analytes inpH 5.5 running buffer at 30 μL/min with a 90 s delay post injection (toallow smooth dissociation for kinetic modelling). 2×12 s regenerationpulses post injection were performed to restore the baseline (HBS-EP pH7.4; 10 μL at 50 μL/min). Analysis was performed on two separateoccasions. The reference cell value was then subtracted andBiaevaluation software 4.1 used to obtain kinetic data and confirm KDvalues.

SPR was used to identify the binding response of variants to FcRn, theresults are shown in Tables 5a and 5b.

TABLE 5a Molecule SEQ ID NO Binding Response (RU) WT rHSA 2 229 HSAK573P 3 300 HSA T83K 35 194 HSA T83K/K573P 38 285 HSA E82A 36 221 HSAE82A/K573P 39 275 HSA E82D 41 227 HSA E82D/K573P 43 269 HSA P110G 42 235HSA P110G/K573P 44 284 HSA L112F 37 253 HSA L112F/K573P 40 290Values shown are a mean of two runs.

TABLE 5b Molecule SEQ ID NO Binding Response (RU) WT rHSA 2 148 HSAK573P 3 181 HSA T83N/N111E 32 167Values shown are a mean of two runs.KD analysis was performed on variants to assess variant-FcRn bindingaffinity relative to HSA-K573-FcRn binding affinity. The results areshown in Table 6. Further analysis was carried out to calculate bindingaffinities (Table 7).

TABLE 6 Binding affinity (fold SEQ ID difference, relative to HSAMolecule NO: KD (μM) wild-type) WT rHSA 2 3.82 — HSA L112F 37 1.44 2.7HSA T83K 35 1.42 2.7 HSA E82A 36 2.81 1.4 HSA K573P 3 0.18 21.2 HSAL112F/K573P 40 0.108 35.4 HSA T83K/K573P 38 0.147 26.0 HSA E82A/K573P 390.174 22.0

TABLE 7 Fold difference SEQ Mean compared ID Ka Kd KD KD to HSA MoleculeNO: (1/Ms) (1/s) (μM) (μM) wild-type WT rHSA 2 0.63 × 10⁴ 0.0133 2.111.97 — 0.78 × 10⁴ 0.0141 1.83 HSA K573P 3 0.81 × 10⁴ 1.32 × 10⁻³ 0.1620.20 9.9 0.74 × 10⁴ 1.77 × 10⁻³ 0.238 HSA 33 2.28 × 10⁴ 1.16 × 10⁻³0.051 0.061 32.3 T83N/N111E/K573P 2.28 × 10⁴ 1.59 × 10⁻³ 0.070 HSAT83N/K573P 34 1.55 × 10⁴  1.3 × 10⁻³ 0.084 0.12 16.4 1.22 × 10⁴ 1.84 ×10⁻³ 0.15

The data show that HSA T83N/N111E/K573P and HSA T83N/K573P have highFcRn binding affinities relative to wild-type HSA. HSA E82A and HSAL112F both show improved binding to FcRn compared to wild-type HSAbinding to FcRn and this suggests that the loops comprising amino acids78 to 88 of HSA (SEQ ID NO: 2) and 105 to 120 of HSA (SEQ ID NO: 2) areinvolved in the binding of HSA to FcRn.

HSA with single mutations at position L112 or T83 show similar FcRnbinding affinities to each other. However, the double mutation of L112and K573 has a stronger binding affinity to FcRn than the doublemutation of T83 and K573.

TABLE 8 SEQ Ka Kd KD Mean KD Molecule ID NO: (10³/MS) (10³/s) (μM) (μM)WT HSA 2 4.3 63.6 13.7 13.8 5.6 77.6 13.9 HSA-K573P 3 4.3 6.2 1.4 1.15.2 4.6 0.89 HSA-E82D 41 2.3 84.3 36.9 24.1 6.5 73.0 11.3 HSA-E82D/K573P43 4.9 6.7 1.4 1.1 5.5 5.0 0.9

The data of Table 8 show that HSA-E82D has a low FcRn binding affinityrelative to wild-type albumin and HSA-K573P has a high FcRn bindingrelative to wild-type albumin. However, the double mutant HSA-E82D/K573Pshows the same FcRn binding affinity as HSA-K573P, i.e. inclusion of theE82D substitution does not adversely affect FcRn binding.

The invention described and claimed herein is not to be limited in scopeby the specific aspects herein disclosed, since these aspects areintended as illustrations of several aspects of the invention. Anyequivalent aspects are intended to be within the scope of thisinvention. Indeed, various modifications of the invention in addition tothose shown and described herein will become apparent to those skilledin the art from the foregoing description. Such modifications are alsointended to fall within the scope of the appended claims. In the case ofconflict, the present disclosure including definitions will control.

1. A polypeptide which is a variant of albumin, fragment thereof orfusion polypeptide comprising said variant albumin or a fragmentthereof, which polypeptide has one or more (several) alterations inDomain I of the albumin, fragment or fusion polypeptide and has one ormore (several) alterations in Domain III of the albumin, fragment orfusion polypeptide and has an altered binding affinity to FcRn comparedwith the binding affinity of a parent albumin, reference albumin,fragment thereof or fusion polypeptide comprising said parent albumin,reference albumin or fragment or fusion thereof to FcRn.
 2. Apolypeptide which is a variant of albumin, fragment thereof or fusionpolypeptide comprising said variant albumin or a fragment thereof, whichpolypeptide has one or more (several) alterations in Domain I of thealbumin, fragment or fusion polypeptide and/or has one or more (several)alterations in Domain III of the albumin, fragment or fusion polypeptideand has an altered binding affinity to FcRn compared with the bindingaffinity of a parent albumin, reference albumin, fragment thereof orfusion polypeptide comprising said parent albumin, reference albumin orfragment or fusion thereof to FcRn wherein the alteration(s) in Domain Iare selected from positions corresponding to any of positions 78 to 120of SEQ ID NO: 2 and the alteration(s) in Domain III are selected frompositions corresponding to any of positions 425, 505, 510, 512, 524,527, 531, 534, 569, 573, 575 of SEQ ID NO:
 2. 3. The polypeptideaccording to claim 1 wherein the one or more (several) alterations inDomain I are selected from positions corresponding to any of positionsfrom 78 to 88 and/or from any of 105 to 120 of SEQ ID NO:
 2. 4. Thepolypeptide according to claim 1 comprising alterations at positionscorresponding to positions (a) 111 and 573; (b) 82 and 83; (c) 82 and111; (d) 82 and 112; (e) 82 and 573; (f) 83 and 111; (g) 83 and 112; (h)83 and 573; (i) 111 and 112; (j) 83, 111, and 573; (k) 112 and 573; (l)82, 83, and 111; (m) 82, 83, and 112; (n) 82, 83, and 573; (o) 82, 111,and 112; (p) 82, 111, and 573; (q) 82, 112, and 573; (r) 83, 111, and112; (s) 83, 112, and 573; (t) 111, 112, and 573; (u) 82, 83, 111, and112; (v) 82, 83, 111, and 573; (w) 82, 83, 112, and 573; (x) 82, 111,112, and 573; (y) 83, 111, 112, and 573; or (z) 82, 83, 111, 112, and573 of SEQ ID NO:
 2. 5. The polypeptide according claim 1 wherein theone or more (several) alterations in Domain I are selected frompositions corresponding to 83 and/or 111 of SEQ ID NO:
 2. 6. Thepolypeptide according to claim 1 wherein the alteration in Domain III isat a position corresponding to 573 of SEQ ID NO:
 2. 7. The polypeptideaccording to claim 1 wherein the alteration in Domain I and/or thealteration in Domain III is a substitution.
 8. The polypeptide of claim2 wherein the alteration at the position corresponding to position 83 isa substitution to N, K or S,
 9. The polypeptide of claim 2 wherein thealteration at the position corresponding to position 111 is asubstitution to D, G, H, R, Q or E.
 10. The polypeptide of claim 5wherein the alteration at the position corresponding to position 573 isa substitution to a P, Y, W, H, F, T, I or V.
 11. The polypeptide ofclaim 5 wherein the substitution at the position corresponding toposition 573 is to a P, Y or W.
 12. The polypeptide of claim 5 whereinthe substitution at the position corresponding to position 573 is to aP.
 13. The polypeptide of claim 1 wherein the reference albumin is HSA(SEQ ID No: 2) or a fragment thereof, or a fusion polypeptide comprisingHSA or a fragment thereof, most preferably SEQ ID NO:
 2. 14. Thepolypeptide according to claim 1, having a stronger binding affinity toFcRn and/or longer plasma half-life than a parent albumin, referencealbumin, fragment thereof or fusion polypeptide comprising said parentalbumin, reference albumin or fragment or fusion thereof.
 15. Thepolypeptide according to claim 1, wherein the sequence identity of thepolypeptide to SEQ ID NO: 2 is more than 80%, preferably more than 90%,more preferred more than 95%, more preferred more than 96%, even morepreferred more than 97%, more preferred more than 98% and most preferredmore than 99%.
 16. A fusion polypeptide comprising a polypeptideaccording to claim 1 and a fusion partner polypeptide selected from atherapeutic, prophylactic, diagnostic, imaging or other beneficialmoiety.
 17. A method for preparing a polypeptide which is a variant ofalbumin, fragment thereof or fusion polypeptide comprising said variantalbumin or fragment thereof having a binding affinity to FcRn which isaltered compared to the binding affinity of a reference albumin,fragment or fusion thereof to FcRn, comprising: (a) Providing a nucleicacid encoding a parent albumin having at least 80% sequence identity toSEQ ID NO: 2; (b) Modifying the nucleic acid sequence of step (a), toencode a polypeptide which is a variant albumin, fragment thereof orfusion polypeptide comprising said variant albumin or fragment thereofcomprising: i. alterations at positions corresponding to one or more(several) positions in Domain I of the parent albumin and one or more(several) positions in Domain III; or ii. alterations at positionscorresponding to one of more of any of positions 78 to 120 of Domain Iof SEQ ID NO: 2 or at positions corresponding to one or more (several)of any of positions 425, 505, 510, 512, 524, 527, 531, 534, 569, 573,575 of Domain III of SEQ ID NO: 2; (c) optionally introducing themodified sequence of step (b) in a suitable host cell; (d) optionallygrowing the cells in a suitable growth medium under condition leading toexpression of the polypeptide; and (e) optionally recovering thepolypeptide from the growth medium; (f) wherein the polypeptide has analtered binding affinity to FcRn and/or an altered plasma half-lifecompared with the half-life of a parent albumin, reference albumin,fragment thereof or fusion polypeptide comprising said parent albumin,reference albumin or fragment or fusion thereof.
 18. The methodaccording to claim 17 wherein the one or more (several) alterations inDomain I are selected from positions corresponding to positions from anyof 78 to 88 and/or from any of 105 to 120 of SEQ ID NO:
 2. 19. Themethod according to claim 17 wherein the polypeptide comprisesalterations corresponding to positions (a) 111 and 573; (b) 82 and 83;(c) 82 and 111; (d) 82 and 112; (e) 82 and 573; (f) 83 and 111; (g) 83and 112; (h) 83 and 573; (i) 111 and 112; (j) 83, 111, and 573; (k) 112,and 573; (l) 82, 83, and 111; (m) 82, 83, and 112; (n) 82, 83, and 573;(o) 82, 111, and 112; (p) 82, 111, and 573; (q) 82, 112, and 573; (r)83, 111, and 112; (s) 83, 112, and 573; (t) 111, 112, and 573; (u) 82,83, 111, and 112; (v) 82, 83, 111, and 573; (w) 82, 83, 112, and 573;(x) 82, 111, 112, and 573; (y) 83, 111, 112, and 573; or (z) 82, 83,111, 112, and 573 of SEQ ID NO:
 2. 20. The method according to claim 17wherein the one or more (several) alterations in Domain I are selectedfrom positions corresponding to 83 and/or 111 of SEQ ID NO:
 2. 21-48.(canceled)